HETEROCYCLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE

Information

  • Patent Application
  • 20230217807
  • Publication Number
    20230217807
  • Date Filed
    December 29, 2022
    a year ago
  • Date Published
    July 06, 2023
    10 months ago
Abstract
Provided are a heterocyclic compound represented by Formula 1, a light-emitting device including the heterocyclic compound, and an electronic apparatus including the light-emitting device:
Description
CROSS-REFERENCE TO RELATED APPLICATION(S)

This application claims priority to and benefits of Korean Patent Application Nos. 10-2022-0001449 and 10-2022-0078481 under 35 U.S.C. § 119, filed on Jan. 5, 2022 and Jun. 27, 2022, respectively, in the Korean Intellectual Property Office, the entire contents of which are incorporated herein by reference.


BACKGROUND
1. Technical Field

Embodiments relate to a heterocyclic compound, a light-emitting device including the heterocyclic compound, and an electronic apparatus including the light-emitting device.


2. Description of the Related Art

From among light-emitting devices, organic light-emitting devices (OLEDs) are self-emissive devices that, as compared with conventional devices, have wide viewing angles, high contrast ratios, short response times, and excellent characteristics in terms of luminance, driving voltage, and response speed, and produce full-color images.


Organic light-emitting devices may include a first electrode on a substrate, and a hole transport region, an emission layer, an electron transport region, and a second electrode sequentially stacked on the first electrode. Holes provided from the first electrode move toward the emission layer through the hole transport region, and electrons provided from the second electrode move toward the emission layer through the electron transport region. Carriers, such as holes and electrons, recombine in the emission layer to produce excitons. These excitons transition from an excited state to a ground state, thereby generating light.


It is to be understood that this background of the technology section is, in part, intended to provide useful background for understanding the technology. However, this background of the technology section may also include ideas, concepts, or recognitions that were not part of what was known or appreciated by those skilled in the pertinent art prior to a corresponding effective filing date of the subject matter disclosed herein.


SUMMARY

Embodiments include a heterocyclic compound, a light-emitting device including the heterocyclic compound, and an electronic apparatus including the light-emitting device.


Additional aspects will be set forth in part in the description which follows and, in part, will be apparent from the description, or may be learned by practice of the embodiments of the disclosure.


According to embodiments, a heterocyclic compound may be represented by Formula 1.




embedded image


In Formulae 1 and 2,


X1 may be N or C(R1),


X2 may be N or C(R2),


X3 may be N or C(R3),


X4 may be N or C(R4),


at least one of X1 to X3 may be N,


Z1 may be a group represented by Formula 2,


n1 may be an integer from 1 to 5,


Y1 may be C or Si,


Ar11 to Ar13 and Ar21 to Ar23 may each independently be a C5-C60 carbocyclic group or a C1-C60 heterocyclic group,


L11 and L21 to L24 may each independently be a single bond, a C5-C60 carbocyclic group unsubstituted or substituted with at least one R10a, or a C1-C60 alkyl group unsubstituted or substituted with at least one R10a,


b11 and b21 to b24 may each independently be an integer from 1 to 3,


E11, E12, and E21 to E23 may each independently be a C5-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 alkyl group unsubstituted or substituted with at least one R10a,


a11, a12, and a21 to a23 may each independently be an integer from 0 to 5, and the sum of a11, a12, and a21 to a23 may be 1 or more,


R1 to R4, R11 to R13, and R21 to R23 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —Si(Q1)(Q2)(Q3), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2),


d11 to d13 and d21 to d23 may each independently be an integer from 0 to 10,


* indicates a binding site to a neighboring atom,


R10a may be:


deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, or a nitro group;


a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, —Si(Q11)(Q12)(Q13), —B(Q11)(Q12), —C(═O)(Q11), —S(═O)2(Q11), —P(═O)(Q11)(Q12), or any combination thereof;


a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, or a C6-C60 arylthio group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, —Si(Q21)(Q22)(Q23), —B(Q21)(Q22), —C(═O)2(Q21), —S(═O)2(Q21), —P(═O)(Q21)(Q22), or any combination thereof; or


—Si(Q31)(Q32)(Q33), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), or —P(═O)(Q31)(Q32), and


Q1 to Q3, Q11 to Q13, Q21 to Q23, and Q31 to Q33 may each independently be: hydrogen; deuterium; —F; —Cl; —Br; —I; a hydroxyl group; a cyano group; a nitro group; a C1-C60 alkyl group; a C2-C60 alkenyl group; a C2-C60 alkynyl group; a C1-C60 alkoxy group; or a C3-C60 carbocyclic group or a C1-C60 heterocyclic group, each unsubstituted or substituted with deuterium, —F, a cyano group, a C1-C60 alkyl group, a C1-C6 alkoxy group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, or any combination thereof.


In an embodiment, X4 may be C(R4), R4 may be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C6 heterocyclic group unsubstituted or substituted with at least one R10a, and R10a is the same as described herein.


In an embodiment, E11, E12, and E21 to E23 may each independently be: a C1-C20 alkyl group; a C1-C20 alkyl group substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C10 alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, or any combination thereof; or a cyclopentenyl group, an adamantanyl group, a norbornanyl group, a phenyl group, a pentalenyl group, a naphthyl group, an azulene group, an indacenyl group, an acenaphthyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a heptalenyl group, a naphthacenyl group, a picenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovalenyl group, an indenyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, an indenophenanthrenyl group, or an indenoanthracenyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a tetrahydronaphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, an azadibenzosilolyl group, —Si(Q31)(Q32)(Q33), —B(Q31)(Q32), —P(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or any combination thereof, and Q31 to Q33 may each be the same as described in Formula 1.


In an embodiment, L11 may be a single bond, and b11 may be 1.


In an embodiment, L24 may be a single bond, and b24 may be 1.


In an embodiment, R1 to R4, R11 to R13, and R21 to R23 may each independently be: hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, or a C1-C20 alkoxy group; a C1-C20 alkyl group or a C1-C20 alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C10 alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, or any combination thereof; a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a tetrahydronaphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, or an azadibenzosilolyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a tetrahydronaphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, an azadibenzosilolyl group, —Si(Q31)(Q32)(Q33), —B(Q31)(Q32), —P(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or any combination thereof; or —Si(Q1)(Q2)(Q3), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2), and Q1 to Q3 and Q31 to Q33 may each independently be: —CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H, or —CD2CDH2; or an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a triazinyl group, a carbazolyl group, a dibenzofuranyl group, or a dibenzothiophenyl group, each unsubstituted or substituted with deuterium, a C1-C10 alkyl group, a phenyl group, a biphenyl group, a pyridinyl group, a pyrimidinyl group, pyridazinyl group, a pyrazinyl group, a triazinyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, or any combination thereof.


In an embodiment, the sum of a21 to a23 may be 1 or more.


In an embodiment, the sum of a11 and a12 may be an integer from 0 to 2.


In an embodiment, in Formula 1, a moiety represented by




embedded image


may be a moiety represented by Formula 1a, which is explained below.


In an embodiment, in Formula 1, a moiety represented by




embedded image


may be a moiety represented by one of Formulae 1 b-1 to 1 b-15, which are explained below.


In an embodiment, in Formula 2, a moiety represented by




embedded image


may be a moiety represented by Formula 2a, which is explained below.


In an embodiment, a group represented by Formula 2 may be a group represented by one of Formulae 2-1 to 2-3, which are explained below.


In an embodiment, the heterocyclic compound represented by Formula 1 may be one of Compounds 1 to 168, which are explained below.


According to embodiments, a light-emitting device may include a first electrode; a second electrode facing the first electrode; and an interlayer between the first electrode and the second electrode, wherein the interlay may include an emission layer, and at least one of the heterocyclic compound.


In an embodiment, the first electrode may be an anode; the second electrode may be a cathode; the interlayer may further include a hole transport region between the emission layer and the first electrode, and an electron transport region between the emission layer and the second electrode; the hole transport region may include a hole injection layer, a hole transport layer, an emission auxiliary layer, an electron blocking layer, or any combination thereof; and the electron transport region may include a buffer layer, a hole blocking layer, an electron control layer, an electron transport layer, an electron injection layer, or any combination thereof.


In an embodiment, the emission layer may include the at least one heterocyclic compound.


In an embodiment, the emission layer may further include an organometallic compound represented by Formula 401, which is explained below.


In an embodiment, the light-emitting device may have a maximum external quantum efficiency equal to or greater than about 20%.


According to embodiments, an electronic apparatus may include the light-emitting device and a thin-film transistor, wherein the thin-film transistor may include a source electrode and a drain electrode, and the first electrode of the light-emitting device may be electrically connected to the source electrode or the drain electrode.


In an embodiment, the electronic apparatus may further include a color filter, a color conversion layer, a touch screen layer, a polarizing layer, or any combination thereof.


It is to be understood that the embodiments above are described in a generic and explanatory sense only and not for the purpose of limitation, and the disclosure is not limited to the embodiments described above.





BRIEF DESCRIPTION OF THE DRAWINGS

The above and other aspects and features of the disclosure will be more apparent by describing in detail embodiments thereof with reference to the accompanying drawings, in which:



FIG. 1 is a schematic cross-sectional view of a light-emitting device according to an embodiment;



FIG. 2 is a schematic cross-sectional view of an electronic apparatus according to an embodiment; and



FIG. 3 is a schematic cross-sectional view of an electronic apparatus according to another embodiment.





DETAILED DESCRIPTION OF THE EMBODIMENTS

The disclosure will now be described more fully hereinafter with reference to the accompanying drawings, in which embodiments are shown. This disclosure may, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the disclosure to those skilled in the art.


In the drawings, the sizes, thicknesses, ratios, and dimensions of the elements may be exaggerated for ease of description and for clarity. Like numbers refer to like elements throughout.


In the description, it will be understood that when an element (or region, layer, part, etc.) is referred to as being “on”, “connected to”, or “coupled to” another element, it can be directly on, connected to, or coupled to the other element, or one or more intervening elements may be present therebetween. In a similar sense, when an element (or region, layer, part, etc.) is described as “covering” another element, it can directly cover the other element, or one or more intervening elements may be present therebetween.


In the description, when an element is “directly on,” “directly connected to,” or “directly coupled to” another element, there are no intervening elements present. For example, “directly on” may mean that two layers or two elements are disposed without an additional element such as an adhesion element therebetween.


As used herein, the expressions used in the singular such as “a,” “an,” and “the,” are intended to include the plural forms as well, unless the context clearly indicates otherwise.


As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items. For example, “A and/or B” may be understood to mean “A, B, or A and B.” The terms “and” and “or” may be used in the conjunctive or disjunctive sense and may be understood to be equivalent to “and/or”.


In the specification and the claims, the term “at least one of” is intended to include the meaning of “at least one selected from the group of” for the purpose of its meaning and interpretation. For example, “at least one of A and B” may be understood to mean “A, B, or A and B.” When preceding a list of elements, the term, “at least one of,” modifies the entire list of elements and does not modify the individual elements of the list.


It will be understood that, although the terms first, second, etc. may be used herein to describe various elements, these elements should not be limited by these terms. These terms are only used to distinguish one element from another element. Thus, a first element could be termed a second element without departing from the teachings of the disclosure. Similarly, a second element could be termed a first element, without departing from the scope of the disclosure.


The spatially relative terms “below”, “beneath”, “lower”, “above”, “upper”, or the like, may be used herein for ease of description to describe the relations between one element or component and another element or component as illustrated in the drawings. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation, in addition to the orientation depicted in the drawings. For example, in the case where a device illustrated in the drawing is turned over, the device positioned “below” or “beneath” another device may be placed “above” another device. Accordingly, the illustrative term “below” may include both the lower and upper positions. The device may also be oriented in other directions and thus the spatially relative terms may be interpreted differently depending on the orientations.


The terms “about” or “approximately” as used herein is inclusive of the stated value and means within an acceptable range of deviation for the recited value as determined by one of ordinary skill in the art, considering the measurement in question and the error associated with measurement of the recited quantity (i.e., the limitations of the measurement system). For example, “about” may mean within one or more standard deviations, or within +20%, 10%, or ±5% of the stated value.


It should be understood that the terms “comprises,” “comprising,” “includes,” “including,” “have,” “having,” “contains,” “containing,” and the like are intended to specify the presence of stated features, integers, steps, operations, elements, components, or combinations thereof in the disclosure, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, or combinations thereof.


Unless otherwise defined or implied herein, all terms (including technical and scientific terms) used have the same meaning as commonly understood by those skilled in the art to which this disclosure pertains. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and should not be interpreted in an ideal or excessively formal sense unless clearly defined in the specification.


A heterocyclic compound according to an embodiment may be represented by Formula 1:




embedded image


In Formula 1, X1 may be N or C(R1), X2 may be N or C(R2), X3 may be N or C(R3), X4 may be N or C(R4), and at least one of X1 to X3 may be N.


In Formula 1, Z1 may be a group represented by Formula 2.


In Formula 1, n1 may be an integer from 1 to 5.


In an embodiment, n1 may be 1.


In Formula 2, Y1 may be C or Si.


In Formulae 1 and 2, Ar11 to Ar13 and Ar21 to Ar23 may each independently be a C5-C60 carbocyclic group or a C1-C60 heterocyclic group.


In Formulae 1 and 2, L11 and L21 to L24 may each independently be a single bond, a C5-C60 carbocyclic group unsubstituted or substituted with at least one R10a, or a C1-C60 alkyl group unsubstituted or substituted with at least one R10a.


In Formulae 1 and 2, b11 and b21 to b24 may each independently be an integer from 1 to 3.


In an embodiment, L11 may be a single bond, and b11 may be 1.


In an embodiment, L24 may be a single bond, and b24 may be 1.


In an embodiment, L21 to L23 may each be a single bond, and b21 to b23 may each be 1.


In Formulae 1 and 2, E11, E12, and E21 to E23 may each independently be a C5-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 alkyl group unsubstituted or substituted with at least one R10a.


In an embodiment, E11, E12, and E21 to E23 may each independently be:


a C1-C20 alkyl group;


a C1-C20 alkyl group substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C10 alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, or any combination thereof; or


a cyclopentenyl group, an adamantanyl group, a norbornanyl group, a phenyl group, a pentalenyl group, a naphthyl group, an azulene group, an indacenyl group, an acenaphthyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a heptalenyl group, a naphthacenyl group, a picenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovalenyl group, an indenyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, an indenophenanthrenyl group, or an indenoanthracenyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a tetrahydronaphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, an azadibenzosilolyl group, —Si(Q31)(Q32)(Q33), —B(Q31)(Q32), —P(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or any combination thereof, and


Q31 to Q33 are each the same as those described herein.


In Formulae 1 and 2, a11, a12, and a21 to a23 may each independently be an integer from 0 to 5, and the sum of a11, a12, and a21 to a23 may be 1 or more.


In an embodiment, the sum of a21 to a23 may be 1 or more.


In an embodiment, a21 may be 1, a22 may be 1, and a23 may be 1;


a21 may be 1, a22 may be 1, and a23 may be 0;


a21 may be 1, a22 may be 0, and a23 may be 1;


a21 may be 0, a22 may be 1, and a23 may be 1;


a21 may be 0, a22 may be 0, and a23 may be 1;


a21 may be 0, a22 may be 1, and a23 may be 0; or


a21 may be 1, a22 may be 0, and a23 may be 0.


In an embodiment, the sum of a11 and a12 may be an integer from 0 to 2.


In an embodiment, the sum of a11, a12, and a21 to a23 may be 2 or more.


In Formulae 1 and 2, R1 to R4, R11 to R13, and R21 to R23 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C6 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C6 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —Si(Q1)(Q2)(Q3), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2).


In an embodiment, R1 to R4, R11 to R13, and R21 to R23 may each independently be: hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, or a C1-C20 alkoxy group;


a C1-C20 alkyl group or a C1-C20 alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C10 alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, or any combination thereof;


a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a tetrahydronaphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, or an azadibenzosilolyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a tetrahydronaphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, an azadibenzosilolyl group, —Si(Q31)(Q32)(Q33), —B(Q31)(Q32), —P(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or any combination thereof; or


—Si(Q1)(Q2)(Q3), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2), and


Q1 to Q3 and Q31 to Q33 may each independently be:


—CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H, or —CD2CDH2; or


an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a triazinyl group, a carbazolyl group, a dibenzofuranyl group, or a dibenzothiophenyl group, each unsubstituted or substituted with deuterium, a C1-C10 alkyl group, a phenyl group, a biphenyl group, a pyridinyl group, a pyrimidinyl group, pyridazinyl group, a pyrazinyl group, a triazinyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, or any combination thereof.


In Formulae 1 and 2, d11 to d13 and d21 to d23 may each independently be an integer from 0 to 10.


In Formula 2, * indicates a binding site to a neighboring atom,


R10a may be:


deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, or a nitro group;


a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, —Si(Q11)(Q12)(Q13), —B(Q11)(Q12), —C(═O)(Q11), —S(═O)2(Q11), —P(═O)(Q11)(Q12), or any combination thereof;


a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, or a C6-C60 arylthio group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, —Si(Q21)(Q22)(Q23), —B(Q21)(Q22), —C(═O)(Q21), —S(═O)2(Q21), —P(═O)(Q21)(Q22), or any combination thereof; or


—Si(Q31)(Q32)(Q33), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), or —P(═O)(Q31)(Q32), and


Q1 to Q3, Q11 to Q13, Q21 to Q23, and Q31 to Q33 may each independently be: hydrogen; deuterium; —F; —Cl; —Br; —I; a hydroxyl group; a cyano group; a nitro group; a C1-C60 alkyl group; a C2-C60 alkenyl group; a C2-C60 alkynyl group; a C1-C60 alkoxy group; or a C3-C60 carbocyclic group or a C1-C60 heterocyclic group, each unsubstituted or substituted with deuterium, —F, a cyano group, a C1-C60 alkyl group, a C1-C60 alkoxy group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, or any combination thereof.


In an embodiment, the heterocyclic compound represented by Formula 1 may include at least one deuterium or not.


For example, the heterocyclic compound represented by Formula 1 may include deuterium as a substituent or a part of a substituent.


In an embodiment, the heterocyclic compound represented by Formula 1 may satisfy at least one of Condition 1 to Condition 13:


[Condition 1]


at least one of d11 R11(s) include deuterium,


[Condition 2]


at least one of d12 R12(s) include deuterium,


[Condition 3]


at least one of d13 R13(s) include deuterium,


[Condition 4]


at least one of b11 L11(s) include deuterium,


[Condition 5]


at least one of d21 R21(s) include deuterium,


[Condition 6]


at least one of d22 R22(s) include deuterium,


[Condition 7]


at least one of d23 R23(s) include deuterium,


[Condition 8]


at least one of b21 L21(s) include deuterium,


[Condition 9]


at least one of b22 L22(s) include deuterium,


[Condition 10]


at least one of b23 L23(s) include deuterium,


[Condition 11]


at least one of b24 L24(s) include deuterium,


[Condition 12]


at least one of R1 to R4 include deuterium,


[Condition 13]


at least one of n1 Z1(s) include deuterium.


In an embodiment, at least two or more of Conditions 1 to 13 may be satisfied.


In an embodiment, at least three of Conditions 1 to 13 may be satisfied.


In an embodiment, at least four of Conditions 1 to 13 may be satisfied.


In an embodiment, at least five of Conditions 1 to 13 may be satisfied.


In an embodiment, at least six of Conditions 1 to 13 may be satisfied.


In an embodiment, at least 7 or more of Conditions 1 to 13 may be satisfied.


In an embodiment, at least eight of Conditions 1 to 13 may be satisfied.


In an embodiment, at least 9 or more of Conditions 1 to 13 may be satisfied.


In an embodiment, at least 10 or more of Conditions 1 to 13 may be satisfied.


In an embodiment, at least 11 or more of Conditions 1 to 13 may be satisfied.


In an embodiment, at least 12 of Conditions 1 to 13 may be satisfied.


In an embodiment, Conditions 1 to 13 may all be satisfied.


In an embodiment, the deuterium substitution rate of the heterocyclic compound represented by Chemical Formula 1 may be greater than 0% and less than or equal to 100%.


In an embodiment, the deuterium substitution rate of the heterocyclic compound represented by Formula 1 may be about 10% or more and about 100% or less. For example, the substitution rate of deuterium is about 10% or more and about 100% or less, about 10% or more and about 90% or less, about 15% or more and about 100% or less, about 15% or more and about 90% or less, about 20% or more and about 100% or less, about 20% or more and about 90% or less, about 40% or more and about 100% or less, or about 40% or more and about 90% or less.


In an embodiment, the deuterium substitution rate of the heterocyclic compound may be about 10% or more and 100% or less.


The term “deuterium substitution rate” refers to a ratio of the number of substituents substituted with deuterium among the number of substituents in the heterocyclic compound represented by Formula 1.


In an embodiment, in Formula 1, a moiety represented by




embedded image


may be a moiety represented by Formula 1a:




embedded image


In Formula 1a,


R13a to R13d are each independently the same as described in connection with R13 in Formula 1,


Z1 is the same as described herein, and


* indicates a binding site to a neighboring atom.


In an embodiment, in Formula 1, a moiety represented by




embedded image


may be a moiety represented by one of Formulae 1b-1 to 1b-15:




embedded image


embedded image


embedded image


In Formulae 1b-1 to 1b-15,


R11a to R11d are each independently the same as described in connection with R11 in Formula 1,


R12a to R12d are each independently the same as described in connection with R12 in Formula 1,


E11 and E12 are each the same as those described herein, and


* indicates a binding site to a neighboring atom.


In an embodiment, in Formulae 1b-1 to 1b-15, R11a, R11b, R11c, R11d, R12a, R12b, R12c, and R12d may each independently be hydrogen or deuterium.


In an embodiment, in Formula 1, a moiety represented by




embedded image


may be a moiety represented by one of Formulae 1bb-1 to 1bb-19:




embedded image


embedded image


embedded image


embedded image


In Formulae 1bb-1 to 1bb-19,


E11 is the same as described herein,


D is deuterium, and


* indicates a binding site to a neighboring atom


In an embodiment, X4 may be C(R4), and


R4 may be hydrogen, deuterium, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, or —Si(Q1)(Q2)(Q3).


In an embodiment, X4 may be C(R4), and


R4 may be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a.


In an embodiment, X4 may be C(R4), and


R4 may be a benzene group, a naphthalene group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a carbazole group, a dibenzofuran group, a dibenzocellopene group, a dibenzothiophene group, a dibenzosilonane group, or a fluorene group, each unsubstituted or substituted with at least one R10a.


In an embodiment, the heterocyclic compound represented by Formula 1 may be represented by one of Formulae 1-1 to 1-6:




embedded image


embedded image


In Formulae 1-1 to 1-6,


Y14 may be N(R14a), O, S, Se, C(R14a)(R14b) or Si(R14a)(R14b),


R14, R14a and R14b are each independently the same as described in connection with R11 in Formula 1,


c15 may be an integer from 1 to 5,


c17 may be an integer from 1 to 7,


c18 may be an integer from 1 to 8,


X1 to X3, Z1, n1, Ar11 to Ar13, L11, b11, E11, E12, a11, a12, R11 to R13 and d11 to d13 are each the same as those described herein.


In an embodiment, in Formula 2, a moiety represented by




embedded image


may be a moiety represented by Formula 2a:




embedded image


In Formula 2a,


E21 and R21 are each the same as those described herein,


d24 may be an integer from 0 to 4, and


* indicates a binding site to a neighboring atom.


In an embodiment, a group represented by Formula 2 may be a group represented by one of Formulae 2-1 to 2-3:




embedded image


In Formulae 2-1 to 2-3,


Y1, E21 to E23, and R21 to R23 are each the same as those described herein,


d24 may be an integer from 0 to 4,


d25 may be an integer from 0 to 5, and


* indicates a binding site to a neighboring atom.


In an embodiment, the heterocyclic compound represented by Formula 1 may be one of Compounds 1 to 168, but embodiments are not limited thereto:




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


The heterocyclic compound represented by Formula 1 may include a carbazole ring and a benzene linker that is substituted with at least one N, and may be substituted with at least one carbocyclic group or at least one alkyl group.


Since the heterocyclic compound includes the carbazole ring and the benzene linker that is substituted with at least one N, hole transporting characteristics may be supplemented, and thus, a light-emitting device employing the heterocyclic compound may have improved lifespan.


Since the heterocyclic compound is substituted with the at least one carbocyclic group or the at least one alkyl group, intramolecular steric hindrance may be increased without affecting an energy level of a moiety represented by Formula 2, so that interaction of the compound with a dopant in an emission layer may be effectively controlled, and thus, the light-emitting device may have improved color purity and driving voltage. When the carbocyclic group or the alkyl group is substituted at a third carbon atom of the carbazole ring, although the compound has low triplet energy as the molecular structure thereof is stabilized, the light-emitting device may exhibit excellent lifespan characteristics.


According to embodiments, provided is a light-emitting device which may include a first electrode; a second electrode facing the first electrode; and an interlayer between the first electrode and the second electrode, wherein the interlayer may include an emission layer, and at least one heterocyclic compound represented by Formula 1.


In an embodiment, the first electrode may be an anode; the second electrode may be a cathode; the interlayer may further include a hole transport region between the emission layer and the first electrode, and an electron transport region between the emission layer and the second electrode; the hole transport region may include a hole injection layer, a hole transport layer, an emission auxiliary layer, an electron blocking layer, or any combination thereof; and the electron transport region may include a buffer layer, a hole blocking layer, an electron control layer, an electron transport layer, an electron injection layer, or any combination thereof.


In an embodiment, the emission layer may include the heterocyclic compound.


In an embodiment, the emission layer may include a host and a dopant, an amount of the host may be greater than an amount of the dopant, and the host may include the heterocyclic compound represented by Formula 1.


In an embodiment, the emission layer may further include a metal-containing compound.


In an embodiment, the emission layer may emit blue light or blue-green light.


In an embodiment, the emission layer may emit light having a maximum emission wavelength in a range of about 400 nm to about 500 nm.


In an embodiment, the emission layer may further include an organometallic compound represented by Formula 401:




embedded image


In Formulae 401 and 402,


M may be a transition metal,


L401 may be a ligand represented by Formula 402,


xc1 may be 1, 2, or 3,


when xc1 is 2 or more, two or more of L401(s) may be identical to or different from each other,


L402 may be an organic ligand,


xc2 may be 0, 1, 2, 3, or 4,


when xc2 is 2 or more, two or more of L402(s) may be identical to or different from each other,


X401 and X402 may each independently be nitrogen or carbon,


ring A401 and ring A402 may each independently be a C3-C60 carbocyclic group or a C1-C60 heterocyclic group,


T401 may be a single bond, *—O—*′, *—S—*′, *—C(═O)—*′, *—N(Q411)-*′, *—C(Q411)(Q412)-*′, *—C(Q411)=C(Q412)-*′, *—C(Q411)=*′, or *═C═*′,


X403 and X404 may each independently be a chemical bond, O, S, N(Q413), B(Q413), P(Q413), C(Q413)(Q414), or Si(Q413)(Q414),


Q411 to Q414 are each independently the same as described in connection with Q1,


R401 and R402 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C20 alkyl group unsubstituted or substituted with at least one R10a, a C1-C20 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, —Si(Q401)(Q402)(Q403), —N(Q401)(Q402), —B(Q401)(Q402), —C(═O)(Q401), —S(═O)2(Q401), or —P(═O)(Q401)(Q402),


Q401 to Q403 are each independently the same as described in connection with Q1,


xc11 and xc12 may each independently be an integer from 0 to 10, and


* and *′ in Formula 402 each indicate a binding site to M in Formula 401.


In an embodiment, the light-emitting device may have a maximum external quantum efficiency equal to or greater than about 20%.


According to embodiments, provided is an electronic apparatus which may include the light-emitting device.


In an embodiment, the electronic apparatus may include the light-emitting device, and a thin-film transistor, wherein the thin-film transistor may include a source electrode and a drain electrode, and the first electrode of the light-emitting device may be electrically connected to the source electrode or the drain electrode.


In an embodiment, the electronic apparatus may further include a color filter, a color conversion layer, a touch screen layer, a polarizing layer, or any combination thereof. For example, the electronic apparatus may be a flat panel display apparatus, but embodiments are not limited thereto.


The electronic apparatus is the same as described herein.


[Description of FIG. 1]



FIG. 1 is a schematic cross-sectional view of a light-emitting device 10 according to an embodiment. The light-emitting device 10 may include a first electrode 110, an interlayer 130, and a second electrode 150.


Hereinafter, the structure of the light-emitting device 10 according to an embodiment and a method of manufacturing the light-emitting device 10 will be described with reference to FIG. 1.


[First Electrode 110]


In FIG. 1, a substrate may be further included under the first electrode 110 or on the second electrode 150. The substrate may be a glass substrate or a plastic substrate. In embodiments, the substrate may be a flexible substrate, and may include plastics with excellent heat resistance and durability, such as polyimide, polyethylene terephthalate (PET), polycarbonate, polyethylene naphthalate, polyarylate (PAR), polyetherimide, or any combination thereof.


The first electrode 110 may be formed by, for example, depositing or sputtering a material for forming the first electrode 110 on the substrate. When the first electrode 110 is an anode, a material for forming the first electrode 110 may be a high work function material that facilitates injection of holes.


The first electrode 110 may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode. When the first electrode 110 is a transmissive electrode, a material for forming the first electrode 110 may include indium tin oxide (ITO), indium zinc oxide (IZO), tin oxide (SnO2), zinc oxide (ZnO), or any combination thereof. In embodiments, when the first electrode 110 is a semi-transmissive electrode or a reflective electrode, a material for forming the first electrode 110 may include magnesium (Mg), silver (Ag), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), magnesium-silver (Mg—Ag), or any combination thereof.


The first electrode 110 may have a structure consisting of a single layer or a structure including multiple layers. For example, the first electrode 110 may have a three-layered structure of ITO/Ag/ITO.


[Interlayer 130]


The interlayer 130 may be disposed on the first electrode 110. The interlayer 130 may include an emission layer.


The interlayer 130 may further include a hole transport region between the first electrode 110 and the emission layer and an electron transport region located between the emission layer and the second electrode 150.


The interlayer 130 may further include, in addition to various organic materials, a metal-containing compound such as an organometallic compound, an inorganic material such as a quantum dot, or the like.


In embodiments, the interlayer 130 may include two or more emitting units stacked between the first electrode 110 and the second electrode 150, and at least one charge generation layer located between the two or more emitting units. When the interlayer 130 includes the two or more emitting units and the at least one charge generation layer as described above, the light-emitting device 10 may be a tandem light-emitting device.


[Hole Transport Region in Interlayer 130]


The hole transport region may have a structure consisting of a layer consisting of a single material, a structure consisting of a layer consisting of different materials, or a structure including multiple layers including different materials.


The hole transport region may include a hole injection layer, a hole transport layer, an emission auxiliary layer, an electron-blocking layer, or any combination thereof.


For example, the hole transport region may have a multi-layered structure including a hole injection layer/hole transport layer structure, a hole injection layer/hole transport layer/emission auxiliary layer structure, a hole injection layer/emission auxiliary layer structure, a hole transport layer/emission auxiliary layer structure, or a hole injection layer/hole transport layer/electron blocking layer structure, wherein the layers of each structure may be stacked from the first electrode 110 in its respective stated order, but the structure of the hole transport region is not limited thereto.


The hole transport region may include a compound represented by Formula 201, a compound represented by Formula 202, or any combination thereof:




embedded image


In Formulae 201 and 202,


L201 to L204 may each independently be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,


L205 may be *—O—*′, *—S—*′, *—N(Q201)-*′, a C1-C20 alkylene group unsubstituted or substituted with at least one R10a, a C2-C20 alkenylene group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,


xa1 to xa4 may each independently be an integer from 0 to 5,


xa5 may be an integer from 1 to 10,


R201 to R204 and Q201 may each independently be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,


R201 and R202 may optionally be linked to each other via a single bond, a C1-C5 alkylene group unsubstituted or substituted with at least one R10a, or a C2-C5 alkenylene group unsubstituted or substituted with at least one R10a to form a C8-C60 polycyclic group (for example, a carbazole group, etc.) unsubstituted or substituted with at least one R10a (for example, see Compound HT16, etc.),


R203 and R204 may optionally be linked to each other via a single bond, a C1-C5 alkylene group unsubstituted or substituted with at least one R10a, or a C2-C5 alkenylene group unsubstituted or substituted with at least one R10a to form a C8-C60 polycyclic group unsubstituted or substituted with at least one R10a, and


na1 may be an integer from 1 to 4.


In embodiments, each of Formulae 201 and 202 may include at least one of groups represented by Formulae CY201 to CY217:




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


In Formulae CY201 to CY217, R10b and R10c may each independently the same as described in connection with R10a, ring CY201 to ring CY204 may each independently be a C3-C20 carbocyclic group or a C1-C20 heterocyclic group, and at least one hydrogen in Formulae CY201 to CY217 may be unsubstituted or substituted with R10a as described herein.


In an embodiment, in Formulae CY201 to CY217, ring CY201 to ring CY204 may each independently be a benzene group, a naphthalene group, a phenanthrene group, or an anthracene group.


In embodiments, each of Formulae 201 and 202 may include at least one of groups represented by Formulae CY201 to CY203.


In embodiments, Formula 201 may include at least one of groups represented by Formulae CY201 to CY203 and at least one of groups represented by Formulae CY204 to CY217.


In embodiments, in Formula 201, xa1 may be 1, R201 may be a group represented by one of Formulae CY201 to CY203, xa2 may be 0, and R202 may be a group represented by one of Formulae CY204 to CY207.


In embodiments, each of Formulae 201 and 202 may not include a group represented by one of Formulae CY201 to CY203.


In embodiments, each of Formulae 201 and 202 may not include a group represented by one of Formulae CY201 to CY203, and may include at least one of groups represented by Formulae CY204 to CY217.


In embodiments, each of Formulae 201 and 202 may not include a group represented by one of Formulae CY201 to CY217.


In embodiments, the hole transport region may include one of Compounds HT1 to HT46, m-MTDATA, TDATA, 2-TNATA, NPB(NPD), β-NPB, TPD, Spiro-TPD, Spiro-NPB, methylated NPB, TAPC, HMTPD, 4,4′,4″-tris(N-carbazolyl)triphenylamine (TCTA), polyaniline/dodecylbenzenesulfonic acid (PANI/DBSA), poly(3,4-ethylenedioxythiophene)/poly(4-styrenesulfonate) (PEDOT/PSS), polyaniline/camphor sulfonic acid (PANI/CSA), polyaniline/poly(4-styrenesulfonate) (PANI/PSS), or any combination thereof:




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


A thickness of the hole transport region may be in a range of about 50 Å to about 10,000 Å. For example, the thickness of the hole transport region may be in a range of about 100 Å to about 4,000 Å. When the hole transport region includes a hole injection layer, a hole transport layer, or any combination thereof, a thickness of the hole injection layer may be in a range of about 100 Å to about 9,000 Å, and a thickness of the hole transport layer may be in a range of about 50 Å to about 2,000 Å. For example, the thickness of the hole injection layer may be in a range of about 100 Å to about 1,000 Å. For example, the thickness of the hole transport layer may be in a range of about 100 Å to about 1,500 Å. When the thicknesses of the hole transport region, the hole injection layer, and the hole transport layer are within these ranges, satisfactory hole transporting characteristics may be obtained without a substantial increase in driving voltage.


The emission auxiliary layer may increase light-emission efficiency by compensating for an optical resonance distance according to a wavelength of light emitted by the emission layer, and the electron blocking layer may block the leakage of electrons from the emission layer to the hole transport region. Materials that may be included in the hole transport region may be included in the emission auxiliary layer and the electron blocking layer.


[p-Dopant]


The hole transport region may further include, in addition to the materials as described above, a charge-generation material for improving conductive properties. The charge-generation material may be uniformly or non-uniformly dispersed in the hole transport region (for example, in the form of a single layer consisting of a charge-generation material).


The charge-generation material may be, for example, a p-dopant.


For example, a lowest unoccupied molecular orbital (LUMO) energy level of the p-dopant may be equal to or less than about −3.5 eV.


In an embodiment, the p-dopant may include a quinone derivative, a cyano group-containing compound, a compound containing element EL1 and element EL2, or any combination thereof.


Examples of the quinone derivative may include TCNQ, F4-TCNQ, and the like.


Examples of the cyano group-containing compound may include HAT-CN, and a compound represented by Formula 221:




embedded image


In Formula 221,


R221 to R223 may each independently be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, and


at least one of R221 to R223 may each independently be a C3-C60 carbocyclic group or a C1-C60 heterocyclic group, each substituted with a cyano group; —F; —Cl; —Br; —I; a C1-C20 alkyl group substituted with a cyano group, —F, —Cl, —Br, —I, or any combination thereof; or any combination thereof.


In the compound containing element EL1 and element EL2, element EL1 may be a metal, a metalloid, or any combination thereof, and element EL2 may be a non-metal, a metalloid, or any combination thereof.


Examples of the metal may include: an alkali metal (for example, lithium (Li), sodium (Na), potassium (K), rubidium (Rb), cesium (Cs), etc.); an alkaline earth metal (for example, beryllium (Be), magnesium (Mg), calcium (Ca), strontium (Sr), barium (Ba), etc.); a transition metal (for example, titanium (Ti), zirconium (Zr), hafnium (Hf), vanadium (V), niobium (Nb), tantalum (Ta), chromium (Cr), molybdenum (Mo), tungsten (W), manganese (Mn), technetium (Tc), rhenium (Re), iron (Fe), ruthenium (Ru), osmium (Os), cobalt (Co), rhodium (Rh), iridium (Ir), nickel (Ni), palladium (Pd), platinum (Pt), copper (Cu), silver (Ag), gold (Au), etc.); a post-transition metal (for example, zinc (Zn), indium (In), tin (Sn), etc.); and a lanthanide metal (for example, lanthanum (La), cerium (Ce), praseodymium (Pr), neodymium (Nd), promethium (Pm), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), lutetium (Lu), etc.).


Examples of the metalloid may include silicon (Si), antimony (Sb), and tellurium (Te).


Examples of the non-metal may include oxygen (O) and a halogen (for example, F, Cl, Br, I, etc.).


In embodiments, the compound containing element EL1 and element EL2 may include a metal oxide, a metal halide (for example, a metal fluoride, a metal chloride, a metal bromide, a metal iodide, etc.), a metalloid halide (for example, a metalloid fluoride, a metalloid chloride, a metalloid bromide, a metalloid iodide, etc.), a metal telluride, or any combination thereof.


Examples of the metal oxide may include tungsten oxide (for example, WO, W2O3, WO2, WO3, W2O5, etc.), vanadium oxide (for example, VO, V2O3, VO2, V2O5, etc.), molybdenum oxide (MoO, Mo2O3, MoO2, MoO3, Mo2O5, etc.), and rhenium oxide (for example, ReO3, etc.).


Examples of the metal halide may include an alkali metal halide, an alkaline earth metal halide, a transition metal halide, a post-transition metal halide, and a lanthanide metal halide.


Examples of the alkali metal halide may include LiF, NaF, KF, RbF, CsF, LiCl, NaCl, KCl, RbCl, CsCl, LiBr, NaBr, KBr, RbBr, CsBr, LiI, NaI, KI, RbI, and CsI.


Examples of the alkaline earth metal halide may include BeF2, MgF2, CaF2, SrF2, BaF2, BeCl2, MgCl2, CaCl2, SrCl2, BaCl2, BeBr2, MgBr2, CaBr2, SrBr2, BaBr2, BeI2, MgI2, CaI2, SrI2, and BaI2.


Examples of the transition metal halide may include a titanium halide (for example, TiF4, TiCl4, TiBr4, TiI4, etc.), a zirconium halide (for example, ZrF4, ZrCl4, ZrBr4, ZrI4, etc.), a hafnium halide (for example, HfF4, HfCl4, HfBr4, HfI4, etc.), a vanadium halide (for example, VF3, VCl3, VBr3, VI3, etc.), a niobium halide (for example, NbF3, NbCl3, NbBr3, NbI3, etc.), a tantalum halide (for example, TaF3, TaCl3, TaBr3, TaI3, etc.), a chromium halide (for example, CrF3, CrCl3, CrBr3, CrI3, etc.), a molybdenum halide (for example, MoF3, MoCl3, MoBr3, MoI3, etc.), a tungsten halide (for example, WF3, WCl3, WBr3, WI3, etc.), a manganese halide (for example, MnF2, MnCl2, MnBr2, MnI2, etc.), a technetium halide (for example, TcF2, TcCl2, TcBr2, TcI2, etc.), a rhenium halide (for example, ReF2, ReCl2, ReBr2, ReI2, etc.), an iron halide (for example, FeF2, FeCl2, FeBr2, FeI2, etc.), a ruthenium halide (for example, RuF2, RuCl2, RuBr2, RuI2, etc.), an osmium halide (for example, OsF2, OSCl2, OsBr2, OsI2, etc.), a cobalt halide (for example, CoF2, CoCl2, CoBr2, CoI2, etc.), a rhodium halide (for example, RhF2, RhCl2, RhBr2, RhI2, etc.), an iridium halide (for example, IrF2, IrCl2, IrBr2, IrI2, etc.), a nickel halide (for example, NiF2, NiCl2, NiBr2, NiI2, etc.), a palladium halide (for example, PdF2, PdCl2, PdBr2, PdI2, etc.), a platinum halide (for example, PtF2, PtCl2, PtBr2, PtI2, etc.), a copper halide (for example, CuF, CuCl, CuBr, CuI, etc.), a silver halide (for example, AgF, AgCl, AgBr, AgI, etc.), and a gold halide (for example, AuF, AuCl, AuBr, AuI, etc.).


Examples of the post-transition metal halide may include a zinc halide (for example, ZnF2, ZnCl2, ZnBr2, ZnI2, etc.), an indium halide (for example, InI3, etc.), and a tin halide (for example, SnI2, etc.).


Examples of the lanthanide metal halide may include YbF, YbF2, YbF3, SmF3, YbCl, YbCl2, YbCl3, SmCl3, YbBr, YbBr2, YbBr3, SmBr3, YbI, YbI2, YbI3, and SmI3.


Examples of the metalloid halide may include an antimony halide (for example, SbCl5, etc.).


Examples of the metal telluride may include an alkali metal telluride (for example, Li2Te, Na2Te, K2Te, Rb2Te, Cs2Te, etc.), an alkaline earth metal telluride (for example, BeTe, MgTe, CaTe, SrTe, BaTe, etc.), a transition metal telluride (for example, TiTe2, ZrTe2, HfTe2, V2Te3, Nb2Te3, Ta2Te3, Cr2Te3, Mo2Te3, W2Te3, MnTe, TcTe, ReTe, FeTe, RuTe, OsTe, CoTe, RhTe, IrTe, NiTe, PdTe, PtTe, Cu2Te, CuTe, Ag2Te, AgTe, Au2Te, etc.), a post-transition metal telluride (for example, ZnTe, etc.), and a lanthanide metal telluride (for example, LaTe, CeTe, PrTe, NdTe, PmTe, EuTe, GdTe, TbTe, DyTe, HoTe, ErTe, TmTe, YbTe, LuTe, etc.).


[Emission Layer in Interlayer 130]


When the light-emitting device 10 is a full-color light-emitting device, the emission layer may be patterned into a red emission layer, a green emission layer, and/or a blue emission layer, according to a subpixel. In embodiments, the emission layer may have a stacked structure of two or more layers of a red emission layer, a green emission layer, and a blue emission layer, in which the two or more layers may contact each other or may be separated from each other to emit white light. In embodiments, the emission layer may have a structure in which two or more materials of a red light-emitting material, a green light-emitting material, and a blue light-emitting material are mixed with each other in a single layer to emit white light.


The emission layer may include a host and a dopant. The dopant may include a phosphorescent dopant, a fluorescent dopant, or any combination thereof.


An amount of the dopant in the emission layer may be in a range of about 0.01 parts by weight to about 15 parts by weight, based on 100 parts by weight of the host.


In embodiments, the emission layer may include a quantum dot.


In embodiments, the emission layer may include a delayed fluorescence material. The delayed fluorescence material may serve as a host or as a dopant in the emission layer.


A thickness of the emission layer may be in a range of about 100 Å to about 1,000 Å. For example, the thickness of the emission layer may be in a range of about 200 Å to about 600 Å. When the thickness of the emission layer is within these ranges, excellent light-emission characteristics may be obtained without a substantial increase in driving voltage.


[Host]


The host may include the heterocyclic compound represented by Formula 1.


In embodiments, the host may further include a compound represented by Formula 301:





[Ar301]xb11-[(L301)xb1-R301]xb21  [Formula 301]


In Formula 301,


Ar301 and L301 may each independently be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,


xb11 may be 1, 2, or 3,


xb1 may be an integer from 0 to 5,


R301 may be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, —Si(Q301)(Q302)(Q303), —N(Q301)(Q302), —B(Q301)(Q302), —C(═O)(Q301), —S(═O)2(Q301), or —P(═O)(Q301)(Q302),


xb21 may be an integer from 1 to 5, and


Q301 to Q303 are each independently the same as described in connection with Q1.


For example, in Formula 301, when xb11 is 2 or more, two or more of Ar301(s) may be linked to each other via a single bond.


In embodiments, the host may include a compound represented by Formula 301-1, a compound represented by Formula 301-2, or any combination thereof:




embedded image


In Formulae 301-1 and 301-2,


ring A301 to ring A304 may each independently be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,


X301 may be O, S, N-[(L304)xb4-R304], C(R304)(R305), or Si(R304)(R305),


xb22 and xb23 may each independently be 0, 1, or 2,


L301, xb1, and R301 are each the same as described herein,


L302 to L304 are each independently the same as described in connection with L301,


xb2 to xb4 are each independently the same as described in connection with xb1, and


R302 to R305 and R311 to R314 are each independently the same as described in connection with R301.


In embodiments, the host may include an alkali earth metal complex, a post-transition metal complex, or any combination thereof. For example, the host may include a Be complex (for example, Compound H55), an Mg complex, a Zn complex, or any combination thereof.


In embodiments, the host may include one of Compounds H1 to H124, 9,10-di(2-naphthyl)anthracene (ADN), 2-methyl-9,10-bis(naphthalen-2-yl)anthracene (MADN), 9,10-di-(2-naphthyl)-2-t-butyl-anthracene (TBADN), 4,4′-bis(N-carbazolyl)-1,1′-biphenyl (CBP), 1,3-di-9-carbazolylbenzene (mCP), 1,3,5-tri(carbazol-9-yl)benzene (TCP), or any combination thereof:




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


[Phosphorescent Dopant]


In embodiments, the phosphorescent dopant may include at least one transition metal as a central metal.


The phosphorescent dopant may include a monodentate ligand, a bidentate ligand, a tridentate ligand, a tetradentate ligand, a pentadentate ligand, a hexadentate ligand, or any combination thereof.


The phosphorescent dopant may be electrically neutral.


For example, the phosphorescent dopant may include an organometallic compound represented by Formula 401:




embedded image


In Formulae 401 and 402,


M may be a transition metal (for example, iridium (Ir), platinum (Pt), palladium (Pd), osmium (Os), titanium (Ti), gold (Au), hafnium (Hf), europium (Eu), terbium (Tb), rhodium (Rh), rhenium (Re), or thulium (Tm)),


L401 may be a ligand represented by Formula 402, and xc1 may be 1, 2, or 3, wherein when xc1 is 2 or more, two or more of L401(s) may be identical to or different from each other,


L402 may be an organic ligand, and xc2 may be 0, 1, 2, 3, or 4, wherein, when xc2 is 2 or more, two or more of L402(s) may be identical to or different from each other,


X401 and X402 may each independently be nitrogen or carbon,


ring A401 and ring A402 may each independently be a C3-C60 carbocyclic group or a C1-C60 heterocyclic group,


T401 may be a single bond, *—O—*′, *—S—*′, *—C(═O)—*′, *—N(Q411)-*′, *—C(Q411)(Q412)-*′, *—C(Q411)=C(Q412)-*′, *—C(Q411)=*′, or *═C═*′,


X403 and X404 may each independently be a chemical bond (for example, a covalent bond or a coordination bond), O, S, N(Q413), B(Q413), P(Q413), C(Q413)(Q414), or Si(Q413)(Q414),


Q411 to Q414 are each independently the same as described in connection with Q1,


R401 and R402 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C20 alkyl group unsubstituted or substituted with at least one R10a, a C1-C20 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, —Si(Q401)(Q402)(Q403), —N(Q401)(Q402), —B(Q401)(Q402), —C(═O)(Q401), —S(═O)2(Q401), or —P(═O)(Q401)(Q402),


Q401 to Q403 are each independently the same as described in connection with Q1,


xc11 and xc12 may each independently be an integer from 0 to 10, and


* and *′ in Formula 402 each indicate a binding site to M in Formula 401.


For example, in Formula 402, X401 may be nitrogen and X402 may be carbon, or each of X401 and X402 may be nitrogen.


In embodiments, in Formula 401, when xc1 is 2 or more, two ring A401(s) in two or more of L401(s) may optionally be linked to each other via T402, which is a linking group, and two ring A402(s) may be optionally linked to each other via T403, which is a linking group (see Compounds PD1 to PD4 and PD7). T402 and T403 are each independently the same as described in connection with T401.


In Formula 401, L402 may be an organic ligand. For example, L402 may include a halogen group, a diketone group (for example, an acetylacetonate group), a carboxylic acid group (for example, a picolinate group), —C(═O), an isonitrile group, a —CN group, a phosphorus group (for example, a phosphine group, a phosphite group, etc.), or any combination thereof.


The phosphorescent dopant may include, for example, one of compounds PD1 to PD25, or any combination thereof:




embedded image


embedded image


embedded image


embedded image


embedded image


[Fluorescent Dopant]


The fluorescent dopant may include an amine group-containing compound, a styryl group-containing compound, or any combination thereof.


For example, the fluorescent dopant may include a compound represented by Formula 501:




embedded image


In Formula 501,


Ar501, L501 to L503, R501, and R502 may each independently be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,


xd1 to xd3 may each independently be 0, 1, 2, or 3, and


xd4 may be 1, 2, 3, 4, 5, or 6.


For example, in Formula 501, Ar501 may be a condensed cyclic group (for example, an anthracene group, a chrysene group, a pyrene group, etc.) in which three or more monocyclic groups are condensed together.


In embodiments, in Formula 501, xd4 may be 2.


For example, the fluorescent dopant may include one of Compounds FD1 to FD36, DPVBi, DPAVBi, or any combination thereof:




embedded image


embedded image


embedded image


embedded image


[Delayed Fluorescence Material]


The emission layer may include a delayed fluorescence material.


In the specification, the delayed fluorescence material may be selected from compounds capable of emitting delayed fluorescence based on a delayed fluorescence emission mechanism.


The delayed fluorescence material included in the emission layer may serve as a host or as a dopant, depending on the type of other materials included in the emission layer.


In an embodiment, a difference between a triplet energy level (eV) of the delayed fluorescence material and a singlet energy level (eV) of the delayed fluorescence material may be equal to or greater than 0 eV and equal to or less than 0.5 eV. When the difference between the triplet energy level (eV) of the delayed fluorescence material and the singlet energy level (eV) of the delayed fluorescence material satisfies the above-described range, up-conversion from the triplet state to the singlet state of the delayed fluorescence materials may effectively occur, and thus, the luminescence efficiency of the light-emitting device 10 may be improved.


For example, the delayed fluorescence material may include a material including at least one electron donor (for example, a π electron-rich C3-C60 cyclic group, such as a carbazole group) and at least one electron acceptor (for example, a sulfoxide group, a cyano group, or a π electron-deficient nitrogen-containing C1-C60 cyclic group); or a material including a C8-C60 polycyclic group in which two or more cyclic groups are condensed while sharing boron (B).


Examples of the delayed fluorescence material may include at least one of Compounds DF1 to DF9:




embedded image


embedded image


embedded image


[Quantum Dot]


The emission layer may include a quantum dot.


In the specification, a quantum dot may be a crystal of a semiconductor compound, and may include any material capable of emitting light of various emission wavelengths according to a size of the crystal.


A diameter of the quantum dot may be, for example, in a range of about 1 nm to about 10 nm.


The quantum dot may be synthesized by a wet chemical process, a organometallic chemical vapor deposition process, a molecular beam epitaxy process, or any process similar thereto.


The wet chemical process is a method that includes mixing a precursor material with an organic solvent and growing a quantum dot particle crystal. When the crystal grows, the organic solvent naturally acts as a dispersant coordinated on the surface of the quantum dot crystal and controls the growth of the crystal so that the growth of quantum dot particles can be controlled through a process which costs lower, and may be more readily performed than vapor deposition methods, such as metal organic chemical vapor deposition (MOCVD) or molecular beam epitaxy (MBE),


The quantum dot may include a Group II-VI semiconductor compound, a Group III-V semiconductor compound, a Group III-VI semiconductor compound, a Group I-III-VI semiconductor compound, a Group IV-VI semiconductor compound, a Group IV element or compound, or any combination thereof.


Examples of the Group II-VI semiconductor compound may include: a binary compound, such as CdS, CdSe, CdTe, ZnS, ZnSe, ZnTe, ZnO, HgS, HgSe, HgTe, MgSe, or MgS; a ternary compound, such as CdSeS, CdSeTe, CdSTe, ZnSeS, ZnSeTe, ZnSTe, HgSeS, HgSeTe, HgSTe, CdZnS, CdZnSe, CdZnTe, CdHgS, CdHgSe, CdHgTe, HgZnS, HgZnSe, HgZnTe, MgZnSe, or MgZnS; a quaternary compound, such as CdZnSeS, CdZnSeTe, CdZnSTe, CdHgSeS, CdHgSeTe, CdHgSTe, HgZnSeS, HgZnSeTe, or HgZnSTe; or any combination thereof.


Examples of the Group III-V semiconductor compound may include: a binary compound, such as GaN, GaP, GaAs, GaSb, AlN, AlP, AlAs, AlSb, InN, InP, InAs, or InSb; a ternary compound, such as GaNP, GaNAs, GaNSb, GaPAs, GaPSb, AlNP, AlNAs, AlNSb, AlPAs, AlPSb, InGaP, InNP, InAlP, InNAs, InNSb, InPAs, InPSb, or GaAlNP; a quaternary compound, such as GaAlNAs, GaAlNSb, GaAlPAs, GaAlPSb, GaInNP, GaInNAs, GaInNSb, GaInPAs, GaInPSb, InAlNP, InAlNAs, InAlNSb, InAlPAs, or InAlPSb; or any combination thereof. In an embodiment, the Group III-V semiconductor compound may further include a Group II element. Examples of the Group III-V semiconductor compound further including a Group II element may include InZnP, InGaZnP, and InAlZnP.


Examples of the Group III-VI semiconductor compound may include: a binary compound, such as GaS, GaSe, Ga2Se3, GaTe, InS, InSe, In2S3, In2Se3, or InTe; a ternary compound, such as InGaS3 or InGaSe3; or any combination thereof.


Examples of the Group I-III-VI semiconductor compound may include: a ternary compound, such as AgInS, AgInS2, CuInS, CuInS2, CuGaO2, AgGaO2, or AgAlO2; or any combination thereof.


Examples of the Group IV-VI semiconductor compound may include: a binary compound, such as SnS, SnSe, SnTe, PbS, PbSe, or PbTe; a ternary compound, such as SnSeS, SnSeTe, SnSTe, PbSeS, PbSeTe, PbSTe, SnPbS, SnPbSe, or SnPbTe; a quaternary compound, such as SnPbSSe, SnPbSeTe, or SnPbSTe; or any combination thereof.


Examples of the Group IV element or compound may include: a single element material, such as Si or Ge; a binary compound, such as SiC or SiGe; or any combination thereof.


Each element included in a multi-element compound, such as a binary compound, a ternary compound, or a quaternary compound, may be present at a uniform concentration or at a non-uniform concentration in a particle.


In an embodiment, the quantum dot may have a single structure in which the concentration of each element in the quantum dot is uniform, or the quantum dot may have a core-shell structure. When the quantum dot has a core-shell structure, a material included in the core and a material included in the shell may be different from each other.


The shell of the quantum dot may serve as a protective layer that prevents chemical degeneration of the core to maintain semiconductor characteristics, and/or may serve as a charging layer that imparts electrophoretic characteristics to the quantum dot. The shell may be a single layer or a multi-layer. An interface between the core and the shell may have a concentration gradient in which the concentration of an element that is present in the shell decreases toward the core.


Examples of the shell of the quantum dot may include a metal oxide, a metalloid oxide, a non-metal oxide, a semiconductor compound, or a combination thereof. Examples of the metal oxide, the metalloid oxide, or the non-metal oxide may include: a binary compound, such as SiO2, Al2O3, TiO2, ZnO, MnO, Mn2O3, Mn3O4, CuO, FeO, Fe2O3, Fe3O4, CoO, Co3O4, or NiO; a ternary compound, such as MgAl2O4, CoFe2O4, NiFe2O4, or CoMn2O4; or any combination thereof. Examples of the semiconductor compound may include, as described herein, a Group II-VI semiconductor compound; a Group III-V semiconductor compound; a Group III-VI semiconductor compound; a Group I-III-VI semiconductor compound; a Group IV-VI semiconductor compound; or any combination thereof. For example, the semiconductor compound may include CdS, CdSe, CdTe, ZnS, ZnSe, ZnTe, ZnSeS, ZnTeS, GaAs, GaP, GaSb, HgS, HgSe, HgTe, InAs, InP, InGaP, InSb, AlAs, AlP, AlSb, or any combination thereof.


A full width at half maximum (FWHM) of an emission wavelength spectrum of the quantum dot may be equal to or less than about 45 nm. For example, a FWHM of an emission wavelength spectrum of the quantum dot may be equal to or less than about 40 nm. For example, a FWHM of an emission wavelength spectrum of the quantum dot may be equal to or less than about 30 nm. Within these ranges, color purity or color reproducibility may be improved. Light emitted through the quantum dot may be emitted in all directions, so that a wide viewing angle may be improved.


The quantum dot may be in the form of a spherical particle, a pyramidal particle, a multi-arm particle, a cubic nanoparticle, a nanotube particle, a nanowire particle, a nanofiber particle, or a nanoplate particle.


Since the energy band gap may be adjusted by controlling the size of the quantum dot, light having various wavelength bands may be obtained from the emission layer including the quantum dot. Accordingly, by using quantum dots of different sizes, a light-emitting device that emits light of various wavelengths may be implemented. In embodiments, the size of the quantum dot may be selected to emit red, green, and/or blue light. For example, the size of the quantum dot may be configured to emit white light by the combination of light of various colors.


[Electron Transport Region in Interlayer 130]


The electron transport region may have a structure consisting of a layer consisting of a single material, a structure consisting of a layer consisting of different materials, or a structure including multiple layers including different materials.


The electron transport region may include a buffer layer, a hole blocking layer, an electron control layer, an electron transport layer, an electron injection layer, or any combination thereof.


For example, the electron transport region may have an electron transport layer/electron injection layer structure, a hole blocking layer/electron transport layer/electron injection layer structure, an electron control layer/electron transport layer/electron injection layer structure, or a buffer layer/electron transport layer/electron injection layer structure, wherein the layers of each structure may be stacked from the emission layer in its respective stated order, but the structure of the electron transport region is not limited thereto.


The electron transport region (for example, the buffer layer, the hole blocking layer, the electron control layer, or the electron transport layer in the electron transport region) may include a metal-free compound including at least one π electron-deficient nitrogen-containing C1-C60 cyclic group.


For example, the electron transport region may include a compound represented by Formula 601:





[Ar601]xe11-[(L601)xe1-R601]xe21  [Formula 601]


In Formula 601,


Ar601 and L601 may each independently be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,


xe11 may be 1, 2, or 3,


xe1 may be 0, 1, 2, 3, 4, or 5,


R601 may be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, —Si(Q601)(Q602)(Q603), —C(═O)(Q601), —S(═O)2(Q601), or —P(═O)(Q601)(Q602),


Q601 to Q603 are each independently the same as described in connection with Q1,


xe21 may be 1, 2, 3, 4, or 5, and


at least one of Ar601, L601, and R601 may each independently be a π electron-deficient nitrogen-containing C1-C60 cyclic group unsubstituted or substituted with at least one R10a.


For example, in Formula 601, when xe11 is 2 or more, two or more of Ar601(s) may be linked to each other via a single bond.


In embodiments, Ar601 in Formula 601 may be a substituted or unsubstituted anthracene group.


In embodiments, the electron transport region may include a compound represented by Formula 601-1:




embedded image


In Formula 601-1,


X614 may be N or C(R614), X615 may be N or C(R615), X616 may be N or C(R616), and at least one of X614 to X616 may be N,


L611 to L613 are each independently the same as described in connection with L601,


xe611 to xe613 are each independently the same as described in connection with xe1,


R611 to R613 are each independently the same as described in connection with R601, and


R614 to R616 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a.


For example, in Formulae 601 and 601-1, xe1 and xe611 to xe613 may each independently be 0, 1, or 2.


The electron transport region may include one of Compounds ET1 to ET45, 2,9-dimethyl-4,7-diphenyl-1, 10-phenanthroline (BCP), 4,7-diphenyl-1,10-phenanthroline (Bphen), Alq3, BAlq, TAZ, NTAZ, or any combination thereof:




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


A thickness of the electron transport region may be in a range of about 100 Å to about 5,000 Å. For example, the thickness of the electron transport region may be in a range of about 160 Å to about 4,000 Å. When the electron transport region includes a buffer layer, a hole blocking layer, an electron control layer, an electron transport layer, or any combination thereof, a thickness of the buffer layer, the hole blocking layer, or the electron control layer may each independently be in a range of about 20 Å to about 1,000 Å, and a thickness of the electron transport layer may be in a range of about 100 Å to about 1,000 Å. For example, the thickness of the buffer layer, the hole blocking layer, or the electron control layer may each independently be in a range of about 30 Å to about 300 Å. For example, the thickness of the electron transport layer may be in a range of about 150 Å to about 500 Å. When the thicknesses of the buffer layer, the hole blocking layer, the electron control layer, the electron transport layer, and/or the electron transport region are within these ranges, satisfactory electron transporting characteristics may be obtained without a substantial increase in driving voltage.


The electron transport region (for example, the electron transport layer in the electron transport region) may further include, in addition to the materials described above, a metal-containing material.


The metal-containing material may include an alkali metal complex, an alkaline earth metal complex, or any combination thereof. A metal ion of the alkali metal complex may be a Li ion, a Na ion, a K ion, a Rb ion, or a Cs ion, and a metal ion of the alkaline earth metal complex may be a Be ion, a Mg ion, a Ca ion, a Sr ion, or a Ba ion. A ligand coordinated with the metal ion of the alkali metal complex or the metal ion of the alkaline earth-metal complex may each independently include hydroxyquinoline, hydroxyisoquinoline, hydroxybenzoquinoline, hydroxyacridine, hydroxyphenanthridine, hydroxyphenyloxazole, hydroxyphenylthiazole, hydroxyphenyloxadiazole, hydroxyphenylthiadiazole, hydroxyphenylpyridine, hydroxyphenylbenzimidazole, hydroxyphenylbenzothiazole, bipyridine, phenanthroline, cyclopentadiene, or any combination thereof.


In an embodiment, the metal-containing material may include a Li complex. The Li complex may include, for example, Compound ET-D1 (LiQ) or Compound ET-D2:




embedded image


The electron transport region may include an electron injection layer that facilitates the injection of electrons from the second electrode 150. The electron injection layer may directly contact the second electrode 150.


The electron injection layer may have a structure consisting of a layer consisting of a single material, a structure consisting of a layer consisting of different materials, or a structure including multiple layers including different materials.


The electron injection layer may include an alkali metal, an alkaline earth metal, a rare earth metal, an alkali metal-containing compound, an alkaline earth metal-containing compound, a rare earth metal-containing compound, an alkali metal complex, an alkaline earth metal complex, a rare earth metal complex, or any combination thereof.


The alkali metal may include Li, Na, K, Rb, Cs, or any combination thereof. The alkaline earth metal may include Mg, Ca, Sr, Ba, or any combination thereof. The rare earth metal may include Sc, Y, Ce, Tb, Yb, Gd, or any combination thereof.


The alkali metal-containing compound, the alkaline earth metal-containing compound, and the rare earth metal-containing compound may include oxides, halides (for example, fluorides, chlorides, bromides, iodides, etc.), or tellurides of the alkali metal, the alkaline earth metal, and the rare earth metal, or any combination thereof.


The alkali metal-containing compound may include: alkali metal oxides, such as Li2O, Cs2O, or K2O; alkali metal halides, such as LiF, NaF, CsF, KF, LiI, NaI, CsI, or KI; or any combination thereof. The alkaline earth metal-containing compound may include an alkaline earth metal compound, such as BaO, SrO, CaO, BaxSr1-xO (wherein x is a real number satisfying the condition of 0<x<1), or BaxCa1-xO (wherein x is a real number satisfying the condition of 0<x<1). The rare earth metal-containing compound may include YbF3, ScF3, Sc2O3, Y2O3, Ce2O3, GdF3, TbF3, YbI3, ScI3, TbI3, or any combination thereof. In embodiments, the rare earth metal-containing compound may include a lanthanide metal telluride. Examples of the lanthanide metal telluride may include LaTe, CeTe, PrTe, NdTe, PmTe, SmTe, EuTe, GdTe, TbTe, DyTe, HoTe, ErTe, TmTe, YbTe, LuTe, La2Te3, Ce2Te3, Pr2Te3, Nd2Te3, Pm2Te3, Sm2Te3, Eu2Te3, Gd2Te3, Tb2Te3, Dy2Te3, Ho2Te3, Er2Te3, Tm2Te3, Yb2Te3, and Lu2Te3.


The alkali metal complex, the alkaline earth-metal complex, and the rare earth metal complex may include one of ions of the alkali metal, ions of the alkaline earth metal, and ions of the rare earth metal, and a ligand bonded to the metal ion (for example, hydroxyquinoline, hydroxyisoquinoline, hydroxybenzoquinoline, hydroxyacridine, hydroxyphenanthridine, hydroxyphenyloxazole, hydroxyphenylthiazole, hydroxyphenyloxadiazole, hydroxyphenylthiadiazole, hydroxyphenylpyridine, hydroxyphenyl benzimidazole, hydroxyphenylbenzothiazole, bipyridine, phenanthroline, cyclopentadiene, or any combination thereof).


The electron injection layer may consist of an alkali metal, an alkaline earth metal, a rare earth metal, an alkali metal-containing compound, an alkaline earth metal-containing compound, a rare earth metal-containing compound, an alkali metal complex, an alkaline earth metal complex, a rare earth metal complex, or any combination thereof, as described above. In embodiments, the electron injection layer may further include an organic material (for example, a compound represented by Formula 601).


In an embodiment, the electron injection layer may consist of an alkali metal-containing compound (for example, an alkali metal halide); or the electron injection layer may consist of an alkali metal-containing compound (for example, an alkali metal halide), and an alkali metal, an alkaline earth metal, a rare earth metal, or any combination thereof. For example, the electron injection layer may be a KI:Yb co-deposited layer, an RbI:Yb co-deposited layer, or the like.


When the electron injection layer further includes an organic material, an alkali metal, an alkaline earth metal, a rare earth metal, an alkali metal-containing compound, an alkaline earth metal-containing compound, a rare earth metal-containing compound, an alkali metal complex, an alkaline earth-metal complex, a rare earth metal complex, or any combination thereof may be uniformly or non-uniformly dispersed in a matrix including the organic material.


A thickness of the electron injection layer may be in a range of about 1 Å to about 100 Å. For example, the thickness of the electron injection layer may be in a range of about 3 Å to about 90 Å. When the thickness of the electron injection layer is within these ranges, satisfactory electron injection characteristics may be obtained without a substantial increase in driving voltage.


[Second Electrode 150]


The second electrode 150 may be disposed on the interlayer 130 as described above. The second electrode 150 may be a cathode, which is an electron injection electrode. The second electrode 150 may include a material having a low-work function, for example, a metal, an alloy, an electrically conductive compound, or any combination thereof.


The second electrode 150 may include lithium (Li), silver (Ag), magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), magnesium-silver (Mg—Ag), ytterbium (Yb), silver-ytterbium (Ag—Yb), ITO, IZO, or any combination thereof. The second electrode 150 may be a transmissive electrode, a semi-transmissive electrode, or a reflective electrode.


The second electrode 150 may have a single-layered structure or a multi-layered structure.


[Capping Layer]


The light-emitting device 10 may include a first capping layer located outside the first electrode 110, and/or a second capping layer located outside the second electrode 150. For example, the light-emitting device 10 may have a structure in which the first capping layer, the first electrode 110, the interlayer 130, and the second electrode 150 are stacked in this stated order, a structure in which the first electrode 110, the interlayer 130, the second electrode 150, and the second capping layer are stacked in this stated order, or a structure in which the first capping layer, the first electrode 110, the interlayer 130, the second electrode 150, and the second capping layer are stacked in this stated order.


Light generated in the emission layer of the interlayer 130 of the light-emitting device 10 may be extracted toward the outside through the first electrode 110, which may be a semi-transmissive electrode or a transmissive electrode, and through the first capping layer. Light generated in the emission layer of the interlayer 130 of the light-emitting device 10 may be extracted toward the outside through the second electrode 150, which may be a semi-transmissive electrode or a transmissive electrode, and through the second capping layer.


The first capping layer and the second capping layer may each increase external luminescence efficiency according to the principle of constructive interference. Accordingly, the light extraction efficiency of the light-emitting device 10 may be increased, so that the luminescence efficiency of the light-emitting device 10 may be improved.


The first capping layer and the second capping layer may each include a material having a refractive index equal to or greater than about 1.6 (with respect to a wavelength of about 589 nm).


The first capping layer and the second capping layer may each independently be an organic capping layer including an organic material, an inorganic capping layer including an inorganic material, or an organic-inorganic composite capping layer including an organic material and an inorganic material.


At least one of the first capping layer and the second capping layer may each independently include a carbocyclic compound, a heterocyclic compound, an amine group-containing compound, a porphine derivative, a phthalocyanine derivative, a naphthalocyanine derivative, an alkali metal complex, an alkaline earth metal complex, or any combination thereof. The carbocyclic compound, the heterocyclic compound, and the amine group-containing compound may optionally be substituted with a substituent including O, N, S, Se, Si, F, Cl, Br, I, or any combination thereof.


In an embodiment, at least one of the first capping layer and the second capping layer may each independently include an amine group-containing compound.


For example, at least one of the first capping layer and the second capping layer may each independently include a compound represented by Formula 201, a compound represented by Formula 202, or any combination thereof.


In embodiments, at least one of the first capping layer and the second capping layer may each independently include one of Compounds HT28 to HT33, one of Compounds CP1 to CP6, β-NPB, or any combination thereof:




embedded image


embedded image


[Film]


The heterocyclic compound represented by Formula 1 may be included in various films. Accordingly, another aspect of the disclosure provides a film which may include the heterocyclic compound represented by Formula 1. The film may be, for example, an optical member (or a light control means) (for example, a color filter, a color conversion member, a capping layer, a light extraction efficiency enhancement layer, a selective light absorbing layer, a polarizing layer, a quantum dot-containing layer, etc.), a light-blocking member (for example, a light reflective layer, a light absorbing layer, etc.), or a protective member (for example, an insulating layer, a dielectric layer, etc.).


[Electronic Apparatus]


The light-emitting device may be included in various electronic apparatuses. For example, the electronic apparatus including the light-emitting device may be a light-emitting apparatus, an authentication apparatus, or the like.


The electronic apparatus (for example, a light-emitting apparatus) may further include, in addition to the light-emitting device, a color filter, a color conversion layer, or a color filter and a color conversion layer. The color filter and/or the color conversion layer may be located in at least one traveling direction of light emitted from the light-emitting device. For example, the light emitted from the light-emitting device may be blue light or white light. The light-emitting device may be the same as described herein. In an embodiment, the color conversion layer may include a quantum dot. The quantum dot may be, for example, a quantum dot as described herein.


The electronic apparatus may include a first substrate. The first substrate may include subpixels, the color filter may include color filter areas respectively corresponding to the subpixels, and the color conversion layer may include color conversion areas respectively corresponding to the subpixels.


A pixel defining film may be located between the subpixels to define each subpixel.


The color filter may further include color filter areas and light-shielding patterns located between the color filter areas, and the color conversion layer may further include color conversion areas and light-shielding patterns located between the color conversion areas.


The color filter areas (or the color conversion areas) may include a first area emitting first color light, a second area emitting second color light, and/or a third area emitting third color light, and the first color light, the second color light, and/or the third color light may have different maximum emission wavelengths from one another. For example, the first color light may be red light, the second color light may be green light, and the third color light may be blue light. In embodiments, the color filter areas (or the color conversion areas) may include quantum dots. For example, the first area may include red quantum dots, the second area may include green quantum dots, and the third area may not include quantum dots. The quantum dot may be the same as described herein. The first area, the second area, and/or the third area may each further include a scatterer.


For example, the light-emitting device may emit first light, the first area may absorb the first light to emit first-first color light, the second area may absorb the first light to emit second-first color light, and the third area may absorb the first light to emit third-first color light. In this regard, the first-first color light, the second-first color light, and the third-first color light may have different maximum emission wavelengths. For example, the first light may be blue light, the first-first color light may be red light, the second-first color light may be green light, and the third-first color light may be blue light.


The electronic apparatus may further include a thin-film transistor, in addition to the light-emitting device as described herein. The thin-film transistor may include a source electrode, a drain electrode, and an active layer, wherein one of the source electrode and the drain electrode may be electrically connected to one of the first electrode and the second electrode of the light-emitting device.


The thin-film transistor may further include a gate electrode, a gate insulating film, and the like.


The active layer may include crystalline silicon, amorphous silicon, an organic semiconductor, an oxide semiconductor, and the like.


The electronic apparatus may further include a sealing portion for sealing the light-emitting device. The sealing portion may be located between the color filter and/or the color conversion layer, and the light-emitting device. The sealing portion may allow light from the light-emitting device to be extracted to the outside, and may simultaneously prevent ambient air and moisture from penetrating into the light-emitting device. The sealing portion may be a sealing substrate including a transparent glass substrate or a plastic substrate. The sealing portion may be a thin-film encapsulation layer including an organic layer and/or an inorganic layer. When the sealing portion is a thin-film encapsulating layer, the electronic apparatus may be flexible.


Various functional layers may be further included on the sealing portion, in addition to the color filter and/or the color conversion layer, according to the use of the electronic apparatus. Examples of the functional layers may include a touch screen layer, a polarizing layer, an authentication apparatus, and the like. The touch screen layer may be a pressure-sensitive touch screen layer, a capacitive touch screen layer, or an infrared touch screen layer. The authentication apparatus may be, for example, a biometric authentication apparatus that authenticates an individual by using biometric information of a living body (for example, fingertips, pupils, etc.).


The authentication apparatus may further include, in addition to the light-emitting device as described above, a biometric information collector.


The electronic apparatus may be applied to various displays, light sources, lighting, personal computers (for example, a mobile personal computer), mobile phones, digital cameras, electronic organizers, electronic dictionaries, electronic game machines, medical instruments (for example, electronic thermometers, sphygmomanometers, blood glucose meters, pulse measurement devices, pulse wave measurement devices, electrocardiogram displays, ultrasonic diagnostic devices, or endoscope displays), fish finders, various measuring instruments, meters (for example, meters for a vehicle, an aircraft, and a vessel), projectors, and the like.


[Description of FIGS. 2 and 3]



FIG. 2 is a schematic cross-sectional view of an electronic apparatus according to an embodiment.


The electronic apparatus of FIG. 2 includes a substrate 100, a thin-film transistor (TFT), a light-emitting device, and an encapsulation portion 300 that seals the light-emitting device.


The substrate 100 may be a flexible substrate, a glass substrate, or a metal substrate. A buffer layer 210 may be disposed on the substrate 100. The buffer layer 210 may prevent penetration of impurities through the substrate 100 and may provide a flat surface on the substrate 100.


The TFT may be disposed on the buffer layer 210. The TFT may include an active layer 220, a gate electrode 240, a source electrode 260, and a drain electrode 270.


The active layer 220 may include an inorganic semiconductor such as silicon or polysilicon, an organic semiconductor, or an oxide semiconductor, and may include a source region, a drain region, and a channel region.


A gate insulating film 230 for insulating the active layer 220 from the gate electrode 240 may be disposed on the active layer 220, and the gate electrode 240 may be disposed on the gate insulating film 230.


An interlayer insulating film 250 may be disposed on the gate electrode 240. The interlayer insulating film 250 may be located between the gate electrode 240 to insulate the gate electrode 240 from the source electrode 260 and between the source electrode 260 and between the gate electrode 240 and the drain electrode 270 to insulate the gate electrode 240 from the drain electrode 270.


The source electrode 260 and the drain electrode 270 may be disposed on the interlayer insulating film 250. The interlayer insulating film 250 and the gate insulating film 230 may be formed to expose the source region and the drain region of the active layer 220, and the source electrode 260 and the drain electrode 270 may respectively contact the exposed portions of the source region and the drain region of the active layer 220.


The TFT is electrically connected to a light-emitting device to drive the light-emitting device, and is covered and protected by a passivation layer 280. The passivation layer 280 may include an inorganic insulating film, an organic insulating film, or any combination thereof. A light-emitting device is provided on the passivation layer 280. The light-emitting device may include a first electrode 110, an interlayer 130, and a second electrode 150.


The first electrode 110 may be disposed on the passivation layer 280. The passivation layer 280 may expose a region of the drain electrode 270 without fully covering the drain electrode 270, and the first electrode 110 may be electrically connected to the exposed region of the drain electrode 270.


A pixel defining layer 290 including an insulating material may be disposed on the first electrode 110. The pixel defining layer 290 may expose a region of the first electrode 110, and the interlayer 130 may be formed in the exposed region of the first electrode 110. The pixel defining layer 290 may be a polyimide or polyacrylic organic film. Although not shown in FIG. 2, at least some layers of the interlayer 130 may extend beyond the upper portion of the pixel defining layer 290 to be provided in the form of a common layer.


The second electrode 150 may be disposed on the interlayer 130, and a capping layer 170 may be further included on the second electrode 150. The capping layer 170 may be formed to cover the second electrode 150.


The encapsulation portion 300 may be disposed on the capping layer 170. The encapsulation portion 300 may be disposed on a light-emitting device to protect the light-emitting device from moisture and/or oxygen. The encapsulation portion 300 may include: an inorganic film including silicon nitride (SiNx), silicon oxide (SiOx), indium tin oxide, indium zinc oxide, or any combination thereof; an organic film including polyethylene terephthalate, polyethylene naphthalate, polycarbonate, polyimide, polyethylene sulfonate, polyoxymethylene, polyarylate, hexamethyldisiloxane, an acrylic resin (for example, polymethyl methacrylate, polyacrylic acid, etc.), an epoxy-based resin (for example, aliphatic glycidyl ether (AGE), etc.), or any combination thereof; or a combination of the inorganic film and the organic film.



FIG. 3 is a schematic cross-sectional view of an electronic apparatus according to another embodiment.


The electronic apparatus of FIG. 3 may differ from the electronic apparatus of FIG. 2, at least in that a light-shielding pattern 500 and a functional region 400 are further included on the encapsulation portion 300. The functional region 400 may be a color filter area, a color conversion area, or a combination of the color filter area and the color conversion area. In an embodiment, the light-emitting device included in the electronic apparatus of FIG. 3 may be a tandem light-emitting device.


[Manufacturing Method]


The layers included in the hole transport region, the emission layer, and the layers included in the electron transport region may be formed in a certain region by using various methods such as vacuum deposition, spin coating, casting, Langmuir-Blodgett (LB) deposition, ink-jet printing, laser-printing, laser-induced thermal imaging, and the like.


When the layers included in the hole transport region, the emission layer, and the layers included in the electron transport region are formed by vacuum deposition, the deposition may be performed at a deposition temperature of about 100° C. to about 500° C., a vacuum degree of about 10−8 torr to about 10−3 torr, and a deposition speed of about 0.01 Å/sec to about 100 Å/sec, depending on a material to be included in a layer to be formed and the structure of a layer to be formed.


Definitions of Terms

The term “C3-C60 carbocyclic group” as used herein may be a cyclic group consisting of carbon as the only ring-forming atoms and having 3 to 60 carbon atoms, and the term “C1-C60 heterocyclic group” as used herein may be a cyclic group that has 1 to 60 carbon atoms and further has, in addition to carbon, at least one heteroatom as a ring-forming atom. The C3-C60 carbocyclic group and the C1-C60 heterocyclic group may each be a monocyclic group consisting of one ring or a polycyclic group in which two or more rings are condensed with each other. For example, the C1-C60 heterocyclic group may have 3 to 61 ring-forming atoms.


The term “cyclic group” as used herein may include both the C3-C60 carbocyclic group or the C1-C60 heterocyclic group.


The term “π electron-rich C3-C60 cyclic group” as used herein may be a cyclic group that has 3 to 60 carbon atoms and may not include *—N═*′ as a ring-forming moiety. The term “π electron-deficient nitrogen-containing C1-C60 cyclic group” as used herein may be a heterocyclic group that has 1 to 60 carbon atoms and may include *—N═*′ as a ring-forming moiety.


In embodiments,


the C3-C60 carbocyclic group may be a T1 group or a cyclic group in which at least two T1 groups are condensed with each other (for example, a cyclopentadiene group, an adamantane group, a norbornane group, a benzene group, a pentalene group, a naphthalene group, an azulene group, an indacene group, an acenaphthylene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a perylene group, a pentaphene group, a heptalene group, a naphthacene group, a picene group, a hexacene group, a pentacene group, a rubicene group, a coronene group, an ovalene group, an indene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, an indenophenanthrene group, or an indenoanthracene group),


the C1-C60 heterocyclic group may be a T2 group, a cyclic group in which at least two T2 groups are condensed with each other, or a cyclic group in which at least one T2 group and at least one T1 group are condensed with each other (for example, a pyrrole group, a thiophene group, a furan group, an indole group, a benzoindole group, a naphthoindole group, an isoindole group, a benzoisoindole group, a naphthoisoindole group, a benzosilole group, a benzothiophene group, a benzofuran group, a carbazole group, a dibenzosilole group, a dibenzothiophene group, a dibenzofuran group, an indenocarbazole group, an indolocarbazole group, a benzofurocarbazole group, a benzothienocarbazole group, a benzosilolocarbazole group, a benzoindolocarbazole group, a benzocarbazole group, a benzonaphthofuran group, a benzonaphthothiophene group, a benzonaphthosilole group, a benzofurodibenzofuran group, a benzofurodibenzothiophene group, a benzothienodibenzothiophene group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an isoxazole group, an oxadiazole group, a thiazole group, an isothiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzoisoxazole group, a benzothiazole group, a benzoisothiazole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a benzoisoquinoline group, a quinoxaline group, a benzoquinoxaline group, a quinazoline group, a benzoquinazoline group, a phenanthroline group, a cinnoline group, a phthalazine group, a naphthyridine group, an imidazopyridine group, an imidazopyrimidine group, an imidazotriazine group, an imidazopyrazine group, an imidazopyridazine group, an azacarbazole group, an azafluorene group, an azadibenzosilole group, an azadibenzothiophene group, an azadibenzofuran group, etc.),


the π electron-rich C3-C60 cyclic group may be a T1 group, a cyclic group in which at least two T1 groups are condensed with each other, a T3 group, a cyclic group in which at least two T3 groups are condensed with each other, or a cyclic group in which at least one T3 group and at least one T1 group are condensed with each other (for example, the C3-C60 carbocyclic group, a 1H-pyrrole group, a silole group, a borole group, a 2H-pyrrole group, a 3H-pyrrole group, a thiophene group, a furan group, an indole group, a benzoindole group, a naphthoindole group, an isoindole group, a benzoisoindole group, a naphthoisoindole group, a benzosilole group, a benzothiophene group, a benzofuran group, a carbazole group, a dibenzosilole group, a dibenzothiophene group, a dibenzofuran group, an indenocarbazole group, an indolocarbazole group, a benzofurocarbazole group, a benzothienocarbazole group, a benzosilolocarbazole group, a benzoindolocarbazole group, a benzocarbazole group, a benzonaphthofuran group, a benzonaphthothiophene group, a benzonaphthosilole group, a benzofurodibenzofuran group, a benzofurodibenzothiophene group, a benzothienodibenzothiophene group, etc.),


the π electron-deficient nitrogen-containing C1-C60 cyclic group may be a T4 group, a cyclic group in which at least two T4 groups are condensed with each other, a cyclic group in which at least one T4 group and at least one T1 group are condensed with each other, a cyclic group in which at least one T4 group and at least one T3 group are condensed with each other, or a cyclic group in which at least one T4 group, at least one T1 group, and at least one T3 group are condensed with one another (for example, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an isoxazole group, an oxadiazole group, a thiazole group, an isothiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzoisoxazole group, a benzothiazole group, a benzoisothiazole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a benzoisoquinoline group, a quinoxaline group, a benzoquinoxaline group, a quinazoline group, a benzoquinazoline group, a phenanthroline group, a cinnoline group, a phthalazine group, a naphthyridine group, an imidazopyridine group, an imidazopyrimidine group, an imidazotriazine group, an imidazopyrazine group, an imidazopyridazine group, an azacarbazole group, an azafluorene group, an azadibenzosilole group, an azadibenzothiophene group, an azadibenzofuran group, etc.),


wherein the T1 group may be a cyclopropane group, a cyclobutane group, a cyclopentane group, a cyclohexane group, a cycloheptane group, a cyclooctane group, a cyclobutene group, a cyclopentene group, a cyclopentadiene group, a cyclohexene group, a cyclohexadiene group, a cycloheptene group, an adamantane group, a norbornane (or bicyclo[2.2.1]heptane) group, a norbornene group, a bicyclo[1.1.1]pentane group, a bicyclo[2.1.1]hexane group, a bicyclo[2.2.2]octane group, or a benzene group,


the T2 group may be a furan group, a thiophene group, a 1H-pyrrole group, a silole group, a borole group, a 2H-pyrrole group, a 3H-pyrrole group, an imidazole group, a pyrazole group, a triazole group, a tetrazole group, an oxazole group, an isoxazole group, an oxadiazole group, a thiazole group, an isothiazole group, a thiadiazole group, an azasilole group, an azaborole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a tetrazine group, a pyrrolidine group, an imidazolidine group, a dihydropyrrole group, a piperidine group, a tetrahydropyridine group, a dihydropyridine group, a hexahydropyrimidine group, a tetrahydropyrimidine group, a dihydropyrimidine group, a piperazine group, a tetrahydropyrazine group, a dihydropyrazine group, a tetrahydropyridazine group, or a dihydropyridazine group,


the T3 group may be a furan group, a thiophene group, a 1H-pyrrole group, a silole group, or a borole group, and


the T4 group may be a 2H-pyrrole group, a 3H-pyrrole group, an imidazole group, a pyrazole group, a triazole group, a tetrazole group, an oxazole group, an isoxazole group, an oxadiazole group, a thiazole group, an isothiazole group, a thiadiazole group, an azasilole group, an azaborole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, or a tetrazine group.


The terms “cyclic group”, “C3-C60 carbocyclic group”, “C1-C60 heterocyclic group”, “π electron-rich C3-C60 cyclic group”, or “π electron-deficient nitrogen-containing C1-C60 cyclic group” as used herein may each be a group condensed to any cyclic group, a monovalent group, or a polyvalent group (for example, a divalent group, a trivalent group, a tetravalent group, etc.) according to the structure of a formula for which the corresponding term is used. For example, a “benzene group” may be a benzo group, a phenyl group, a phenylene group, or the like, which may be readily understood by one of ordinary skill in the art according to the structure of a formula including the “benzene group.”


Examples of the monovalent C3-C60 carbocyclic group and the monovalent C1-C60 heterocyclic group may include a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C1-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, and examples of the divalent C3-C60 carbocyclic group and the divalent C1-C60 heterocyclic group may include a C3-C10 cycloalkylene group, a C1-C10 heterocycloalkylene group, a C3-C10 cycloalkenylene group, a C1-C10 heterocycloalkenylene group, a C6-C60 arylene group, a C1-C60 heteroarylene group, a divalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted divalent non-aromatic condensed heteropolycyclic group.


The term “C1-C60 alkyl group” as used herein may be a linear or branched aliphatic hydrocarbon monovalent group that has 1 to 60 carbon atoms, and examples thereof may include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, a sec-isopentyl group, an n-hexyl group, an isohexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an isoheptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an isooctyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an isononyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an isodecyl group, a sec-decyl group, and a tert-decyl group. The term “C1-C60 alkylene group” as used herein may be a divalent group having a same structure as the C1-C60 alkyl group.


The term “C2-C60 alkenyl group” as used herein may be a monovalent hydrocarbon group having at least one carbon-carbon double bond in the middle or at a terminus of the C2-C60 alkyl group, and examples thereof may include an ethenyl group, a propenyl group, and a butenyl group. The term “C2-C60 alkenylene group” as used herein may be a divalent group having a same structure as the C2-C60 alkenyl group.


The term “C2-C60 alkynyl group” as used herein may be a monovalent hydrocarbon group having at least one carbon-carbon triple bond in the middle or at a terminus of the C2-C60 alkyl group, and examples thereof may include an ethynyl group and a propynyl group. The term “C2-C60 alkynylene group” as used herein may be a divalent group having a same structure as the C2-C60 alkynyl group.


The term “C1-C60 alkoxy group” as used herein may be a monovalent group represented by —O(A101) (wherein A101 may be a C1-C60 alkyl group), and examples thereof may include a methoxy group, an ethoxy group, and an isopropyloxy group.


The term “C3-C10 cycloalkyl group” as used herein may be a monovalent saturated hydrocarbon cyclic group having 3 to 10 carbon atoms, and examples thereof may include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group (or bicyclo[2.2.1]heptyl group), a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, and a bicyclo[2.2.2]octyl group. The term “C3-C10 cycloalkylene group” as used herein may be a divalent group having a same structure as the C3-C10 cycloalkyl group.


The term “C1-C10 heterocycloalkyl group” as used herein may be a monovalent cyclic group that further includes, in addition to a carbon atom, at least one heteroatom as a ring-forming atom and has 1 to 10 carbon atoms, and examples thereof may include a 1,2,3,4-oxatriazolidinyl group, a tetrahydrofuranyl group, and a tetrahydrothiophenyl group. The term “C1-C10 heterocycloalkylene group” as used herein may be a divalent group having a same structure as the C1-C10 heterocycloalkyl group.


The term “C3-C10 cycloalkenyl group” as used herein may be a monovalent cyclic group that has 3 to 10 carbon atoms and at least one carbon-carbon double bond in the ring thereof and no aromaticity, and examples thereof may include a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group. The term “C3-C10 cycloalkenylene group” as used herein may be a divalent group having a same structure as the C3-C10 cycloalkenyl group.


The term “C1-C10 heterocycloalkenyl group” as used herein may be a monovalent cyclic group that has, in addition to a carbon atom, at least one heteroatom as a ring-forming atom, 1 to 10 carbon atoms, and at least one carbon-carbon double bond in the cyclic structure thereof. Examples of the C1-C10 heterocycloalkenyl group may include a 4,5-dihydro-1,2,3,4-oxatriazolyl group, a 2,3-dihydrofuranyl group, and a 2,3-dihydrothiophenyl group. The term “C1-C10 heterocycloalkenylene group” as used herein may be a divalent group having a same structure as the C1-C10 heterocycloalkenyl group.


The term “C6-C60 aryl group” as used herein may be a monovalent group having a carbocyclic aromatic system of 6 to 60 carbon atoms, and the term “C6-C60 arylene group” as used herein may be a divalent group having a carbocyclic aromatic system of 6 to 60 carbon atoms. Examples of the C6-C60 aryl group may include a phenyl group, a pentalenyl group, a naphthyl group, an azulenyl group, an indacenyl group, an acenaphthyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a heptalenyl group, a naphthacenyl group, a picenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, and an ovalenyl group. When the C6-C60 aryl group and the C6-C60 arylene group each include two or more rings, the respective rings may be condensed with each other.


The term “C1-C60 heteroaryl group” as used herein may be a monovalent group having a heterocyclic aromatic system of 1 to 60 carbon atoms, further including, in addition to carbon atoms, at least one heteroatom, as ring-forming atoms. The term “C1-C60 heteroarylene group” as used herein may be a divalent group having a heterocyclic aromatic system of 1 to 60 carbon atoms, further including, in addition to carbon atoms, at least one heteroatom, as ring-forming atoms. Examples of the C1-C60 heteroaryl group may include a pyridinyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, a benzoquinolinyl group, an isoquinolinyl group, a benzoisoquinolinyl group, a quinoxalinyl group, a benzoquinoxalinyl group, a quinazolinyl group, a benzoquinazolinyl group, a cinnolinyl group, a phenanthrolinyl group, a phthalazinyl group, and a naphthyridinyl group. When the C1-C60 heteroaryl group and the C1-C60 heteroarylene group each include two or more rings, the respective rings may be condensed with each other.


The term “monovalent non-aromatic condensed polycyclic group” as used herein may be a monovalent group (for example, having 8 to 60 carbon atoms) having two or more rings condensed to each other, only carbon atoms as ring-forming atoms, and no aromaticity in its entire molecular structure. Examples of the monovalent non-aromatic condensed polycyclic group may include an indenyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, an indenophenanthrenyl group, and an indenoanthracenyl group. The term “divalent non-aromatic condensed polycyclic group” as used herein may be a divalent group having a same structure as the monovalent non-aromatic condensed polycyclic group described above.


The term “monovalent non-aromatic condensed heteropolycyclic group” as used herein may be a monovalent group (for example, having 1 to 60 carbon atoms) having two or more rings condensed to each other, further including, in addition to carbon atoms, at least one heteroatom, as ring-forming atoms, and having non-aromaticity in its entire molecular structure. Examples of the monovalent non-aromatic condensed heteropolycyclic group may include a pyrrolyl group, a thiophenyl group, a furanyl group, an indolyl group, a benzoindolyl group, a naphthoindolyl group, an isoindolyl group, a benzoisoindolyl group, a naphthoisoindolyl group, a benzosilolyl group, a benzothiophenyl group, a benzofuranyl group, a carbazolyl group, a dibenzosilolyl group, a dibenzothiophenyl group, a dibenzofuranyl group, an azacarbazolyl group, an azafluorenyl group, an azadibenzosilolyl group, an azadibenzothiophenyl group, an azadibenzofuranyl group, a pyrazolyl group, an imidazolyl group, a triazolyl group, a tetrazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, an oxadiazolyl group, a thiadiazolyl group, a benzopyrazolyl group, a benzimidazolyl group, a benzoxazolyl group, a benzothiazolyl group, a benzoxadiazolyl group, a benzothiadiazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an imidazotriazinyl group, an imidazopyrazinyl group, an imidazopyridazinyl group, an indeno carbazolyl group, an indolocarbazolyl group, a benzofurocarbazolyl group, a benzothienocarbazolyl group, a benzosilolocarbazolyl group, a benzoindolocarbazolyl group, a benzocarbazolyl group, a benzonaphthofuranyl group, a benzonaphthothiophenyl group, a benzonaphtho silolyl group, a benzofurodibenzofuranyl group, a benzofurodibenzothiophenyl group, and a benzothienodibenzothiophenyl group. The term “divalent non-aromatic condensed heteropolycyclic group” as used herein may be a divalent group having a same structure as the monovalent non-aromatic condensed heteropolycyclic group.


The term “C6-C60 aryloxy group” as used herein may be a group represented by —O(A102) (wherein A102 may be a C6-C60 aryl group), and the term “C6-C60 arylthio group” as used herein may be a group represented by —S(A103) (wherein A103 may be a C6-C60 aryl group).


The term “C7-C60 arylalkyl group” as used herein may be a group represented by -(A104)(A105) (wherein A104 may be a C1-C54 alkylene group, and A105 may be a C6-C59 aryl group), and the term “C2-C60 heteroarylalkyl group” as used herein may be a group represented by -(A106)(A107) (wherein A106 may be a C1-C59 alkylene group, and A107 may be a C1-C59 heteroaryl group).


The term “R10a” as used herein may be:


deuterium (-D), —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, or a nitro group;


a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C7-C60 arylalkyl group, a C2-C60 heteroarylalkyl group, —Si(Q11)(Q12)(Q13), —N(Q11)(Q12), —B(Q11)(Q12), —C(═O)(Q11), —S(═O)2(Q11), —P(═O)(Q11)(Q12), or any combination thereof;


a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C7-C60 aryl alkyl group, or a C2-C60 heteroaryl alkyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C7-C60 aryl alkyl group, a C2-C60 heteroaryl alkyl group, —Si(Q21)(Q22)(Q23), —N(Q21)(Q22), —B(Q21)(Q22), —C(═O)(Q21), —S(═O)2(Q21), —P(═O)(Q21)(Q22), or any combination thereof; or


—Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), or —P(═O)(Q31)(Q32).


The groups Q1 to Q3, Q11 to Q13, Q21 to Q23 and Q31 to Q33 as used herein may each independently be: hydrogen; deuterium; —F; —Cl; —Br; —I; a hydroxyl group; a cyano group; a nitro group; a C1-C60 alkyl group; a C2-C60 alkenyl group; a C2-C60 alkynyl group; a C1-C60 alkoxy group; a C3-C60 carbocyclic group or a C1-C60 heterocyclic group, each unsubstituted or substituted with deuterium, —F, a cyano group, a C1-C60 alkyl group, a C1-C60 alkoxy group, a phenyl group, a biphenyl group, or any combination thereof; a C7-C60 arylalkyl group; or a C2-C60 heteroarylalkyl group.


The term “heteroatom” as used herein may be any atom other than a carbon atom or a hydrogen atom. Examples of the heteroatom may include O, S, N, P, Si, B, Ge, Se, or any combination thereof.


The term “third-row transition metal” as used herein may include hafnium (Hf), tantalum (Ta), tungsten (W), rhenium (Re), osmium (Os), iridium (Ir), platinum (Pt), and gold (Au).


The term “Ph” as used herein refers to a phenyl group, the term “Me” as used herein refers to a methyl group, the term “Et” as used herein refers to an ethyl group, the terms “ter-Bu” or “But” as used herein each refer to a tert-butyl group, and the term “OMe” as used herein refers to a methoxy group.


The term “biphenyl group” as used herein may be a “phenyl group substituted with a phenyl group.” For example, the “biphenyl group” may be a substituted phenyl group having a C6-C60 aryl group as a substituent.


The term “terphenyl group” as used herein may be a “phenyl group substituted with a biphenyl group”. For example, the “terphenyl group” may be a substituted phenyl group having, as a substituent, a C6-C60 aryl group substituted with a C6-C60 aryl group.


The symbols * and *′ as used herein, unless defined otherwise, each refer to a binding site to a neighboring atom in a corresponding formula or moiety.


Hereinafter, compounds according to embodiments and light-emitting devices according to embodiments will be described in detail with reference to the Synthesis Examples and the Examples. The wording “B was used instead of A” used in describing Synthesis Examples means that an identical molar equivalent of B was used in place of A.


EXAMPLES
Synthesis Example 1: Synthesis of Compound 4



embedded image


Synthesis of Intermediate 4-1

20 g of bis(3-bromophenyl)diphenylsilane (CAS: 500886-98-6), 4.9 g of phenylboronic acid, 30.35 mL of 2M K2CO3 aqueous solution, and 2.34 g of Pd(PPh3)4 were dissolved in 200 mL of THF solvent, and stirred at 80° C. for 12 hours. After the reaction was completed, the reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography to obtain 14.52 g (yield of 73%) of Intermediate 4-1. Intermediate 4-1 was identified by LC-MS. (C30H23BrSi: M+1 491.50)


Synthesis of Intermediate 4-2

14.52 g of Intermediate 4-1 was dissolved in 200 mL of THF, and stabilized at −78° C. After 30 minutes, 14.18 mL of n-BuLi was slowly added dropwise thereto at −78° C. After 1 hour, 6.38 mL of trimethly borate was rapidly added thereto, the mixture was reacted at room temperature for 12 hours. 200 mL of 2M HCl aqueous solution was added thereto, and the mixture was reacted for 30 minutes. The reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography to obtain 8.63 g (yield of 64%) of Intermediate 4-2. Intermediate 4-2 was identified by LC-MS. (C30H25BO2Si: M+1 456.42)


Synthesis of Compound 4

2 g of 9,9′-(6-chloro-1,3,5-triazine-2,4-diyl)bis(9H-carbazole) (CAS: 877615-05-9), 2.05 g of Intermediate 4-2, 3.36 mL of 2M K2CO3 aqueous solution, and 0.26 g of Pd(PPh3)4 were dissolved in 20 mL of toluene/ethanol (volume ratio of 4:1) solvent, and stirred at 110° C. for 12 hours. After the reaction was completed, the reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography, followed by recrystallization and sublimation purification to obtain 3.2 g (yield of 87%) of Compound 4 with high purity. Compound 4 was identified by LC-MS and 1H-NMR.


Synthesis Example 2: Synthesis of Compound 5



embedded image


Synthesis of Intermediate 5-1

A total of three reactors were prepared.


[Reaction 5A] 20 g of 1,3-dibromobenzene was dissolved in 40 mL of diethyl ether and stabilized at −78° C. After 33.91 mL of n-BuLi was slowly added dropwise thereto at −78° C., the mixture was reacted at a low temperature for 2 hours.


[Reaction 5B] 17.93 g of trichlorophenylsilane was dissolved in 80 mL of diethyl ether and stabilized at −78° C. The entire amount of Reaction 5 Å solution was added to Reaction 5B at −78° C. using a cannula.


[Reaction 5C] 39.5 g of 3-bromo-1,1′-biphenyl (CAS: 2113-57-7) was dissolved in 160 mL of THF and stabilized at −78° C. 67.8 mL of n-BuLi was slowly added dropwise thereto at −78° C. After 1 hour, the entire amount of Reaction 5C solution was added to Reaction 5B at −78° C. using a cannula. After 10 minutes, the mixture was stirred at room temperature for 12 hours. After the reaction was completed, the reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography to obtain 21.65 g (yield of 45%) of Intermediate 5-1. Intermediate 5-1 was identified by LC-MS. (C36H27BrSi: M+1 567.60)


Synthesis of Intermediate 5-2

21.65 g of Intermediate 5-1 was dissolved in 200 mL of THF solvent, and stabilized at −78° C. After 18.31 mL of n-BuLi was slowly added dropwise thereto, the mixture was stirred at a low temperature for 1 hour. After 6.38 mL of trimethly borate was rapidly added thereto, the mixture was stirred at room temperature for 12 hours. 200 mL of 2M HCl was added thereto, and the mixture was stirred for 30 minutes to complete the reaction. The reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography to obtain 13 g (yield of 64%) of Intermediate 5-2. Intermediate 5-2 was identified by LC-MS. (C36H29BO2Si: M+1 532.52)




embedded image


Synthesis of Compound 5

2 g of 9,9′-(6-chloro-1,3,5-triazine-2,4-diyl)bis(9H-carbazole) (CAS: 877615-05-9), 2.39 g of Intermediate 5-2, 3.36 mL of 2M K2CO3 aqueous solution, and 0.26 g of Pd(PPh3)4 were dissolved in 20 mL of toluene/ethanol (volume ratio of 4:1) solvent, and stirred at 110° C. for 12 hours. After the reaction was completed, the reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography, followed by recrystallization and sublimation purification to obtain 3.36 g (yield of 91%) of Compound 5 with high purity. Compound 5 was identified by LC-MS and 1H-NMR.


Synthesis Example 3: Synthesis of Compound 6



embedded image


Synthesis of Intermediate 6-1

20 g of tetrakis(3-bromophenyl)silane (CAS: 553611-81-7), 3.74 g of phenylboronic acid, 23 mL of 2M K2CO3 solution, and 1.77 g of Pd(PPh3)4 were dissolved in 150 mL of THF solvent, and stirred at 80° C. for 12 hours. After the reaction was completed, the reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography to obtain 20.67 g (yield of 82%) of Intermediate 6-1. Intermediate 6-1 was identified by LC-MS. (C42H31BrSi: M+1 643.70)


Synthesis of Intermediate 6-2

20.67 g of Intermediate 6-1 was dissolved in 200 mL of THF solvent, and stabilized at −78° C. After 15.41 mL of n-BuLi was slowly added dropwise thereto, the mixture was stirred at a low temperature for 1 hour. After 5.37 mL of trimethly borate was rapidly added thereto, the mixture was stirred at room temperature for 12 hours. 200 mL of 2M HCl was added thereto, and the mixture was stirred for 30 minutes to complete the reaction. The reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography to obtain 12.12 g (yield of 62%) of Intermediate 6-2. Intermediate 6-2 was identified by LC-MS. (C42H33BO2Si: M+1 608.62)


Synthesis of Compound 6

2 g of 9,9′-(6-chloro-1,3,5-triazine-2,4-diyl)bis(9H-carbazole) (CAS: 877615-05-9), 2.73 g of Intermediate 6-2, 3.36 mL of 2M K2CO3 aqueous solution, and 0.26 g of Pd(PPh3)4 were dissolved in 20 mL of toluene/ethanol (volume ratio of 4:1) solvent, and stirred at 110° C. for 12 hours. After the reaction was completed, the reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography, followed by recrystallization and sublimation purification to obtain 3.85 g (yield of 88%) of Compound 6 with high purity. Compound 6 was identified by LC-MS and 1H-NMR.


Synthesis Example 4: Synthesis of Compound 25



embedded image


Synthesis of Intermediate 25-1

20 g of 3-bromocarbazole (CAS: 1592-95-6), 9.91 g of phenylboronic acid, 61 mL of 2M K2CO3 aqueous solution, and 4.69 g of Pd(PPh3)4 were dissolved in 400 mL of THF solvent, and stirred at 80° C. for 12 hours. After the reaction was completed, the reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography to obtain 19.18 g (yield of 97%) of Intermediate 25-1. Intermediate 25-1 was identified by LC-MS. (C18H13N: M+1 243.31)


Synthesis of Intermediate 25-2

10 g of 9-(4,6-dichloro-1,3,5-triazin-2-yl)-9H-carbazole (CAS: 24209-95-8), 15.93 g of Intermediate 4-2, 23.8 mL of 2M K2CO3 aqueous solution, and 16 mg of PdCl2(PPh3)2 were dissolved in 200 mL of THF solvent, and stirred at 60° C. for 12 hours. The reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography to obtain 16.67 g (yield of 76%) of Intermediate 25-2. Intermediate 25-2 was identified by LC-MS. (C45H31ClN4Si: M+1 691.31)


Synthesis of Compound 25

3 g of Intermediate 25-2, 1.06 g of Intermediate 25-1, 1.38 g of K3PO4, and 0.26 g of 4-(dimethylamino)pyridine (DMAP) were dissolved in 20 mL of DMF solvent, and stirred at 100° C. for 4 hours. After the reaction was completed, the reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography, followed by recrystallization and sublimation purification to obtain 3.35 g (yield of 86%) of Compound 25 with high purity. Compound 25 was identified by LC-MS and 1H-NMR.


Synthesis Example 5: Synthesis of Compound 26



embedded image


Synthesis of Intermediate 26-1

10 g of 9-(4,6-dichloro-1,3,5-triazin-2-yl)-9H-carbazole (CAS: 24209-95-8), 16.89 g of Intermediate 5-2, 23.79 mL of 2M K2CO3 aqueous solution, and 13 mg of PdCl2(PPh3)2 were dissolved in 150 mL of THF solvent, and stirred at 60° C. for 12 hours. After the reaction was completed, the reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography to obtain 14.85 g (yield of 61%) of Intermediate 26-1. Intermediate 26-1 was identified by LC-MS. (C51H35ClN4Si: M+1 767.40)


Synthesis of Compound 26

2 g of Intermediate 26-1, 0.63 g of Intermediate 25-1, 0.83 g of K3PO4, and 0.23 g of DMAP were dissolved in 20 mL of DMF solvent, and stirred at 100° C. for 4 hours. After the reaction was completed, the reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography, followed by recrystallization and sublimation purification to obtain 2.13 g (yield of 84%) of Compound 26 with high purity. Compound 26 was identified by LC-MS and 1H-NMR.


Synthesis Example 6: Synthesis of Compound 27



embedded image


Synthesis of Intermediate 27-1

10 g of 9-(4,6-dichloro-1,3,5-triazin-2-yl)-9H-carbazole, 19.31 g of Intermediate 6-2, 23.79 mL of 2M K2CO3 aqueous solution, and 12 mg of PdCl2(PPh3)2 were dissolved in 120 mL of THF solvent, and stirred at 60° C. for 12 hours. After the reaction was completed, the reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography to obtain 21.41 g (yield of 80%) of Intermediate 27-1. Intermediate 27-1 was identified by LC-MS. (C57H39ClN4Si: M+1 843.50)


Synthesis of Compound 27

2 g of Intermediate 27-1, 0.58 g of Intermediate 25-1, 0.75 g of K3PO4, and 43 mg of DMAP were dissolved in 20 mL of DMF solvent, and stirred at 100° C. for 4 hours. After the reaction was completed, the reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography, followed by recrystallization and sublimation purification to obtain 2 g (yield of 87%) of Compound 27 with high purity. Compound 27 was identified by LC-MS and 1H-NMR.


Synthesis Example 7: Synthesis of Compound 55



embedded image


Synthesis of Intermediate 55-1

10 g of 2,4,6-Trichloropyrimidine (CAS: 3764-01-0), 24.88 g of Intermediate 4-2, 110 mL of 1M Na2CO3 aqueous solution, 1.22 g of Pd(OAc)2, and 2.86 g of PPh3 were dissolved in 330 mL of THF/d·H2O (volume ratio of 1:1) solvent, and stirred at 70° C. for 12 hours. After the reaction was completed, the reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography to obtain 24.7 g (yield of 81%) of Intermediate 55-1. Intermediate 55-1 was identified by LC-MS. (C34H24Cl2N2Si: M+1 559.57)


Synthesis of Compound 55

6.69 g of Intermediate 55-1, 2 g of carbazole, 3.44 g of NaOtBu, 0.82 g of Pd2(dba)3, and 0.49 g of Sphos were dissolved in 50 mL of o-Xylene solvent, and stirred at 150° C. for 12 hours. After the reaction was completed, the reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography, followed by recrystallization and sublimation purification to obtain 8.84 g (yield of 90%) of Compound 55 with high purity. Compound 55 was identified by LC-MS and 1H-NMR.


Synthesis Example 8: Synthesis of Compound 137



embedded image


embedded image


Synthesis of Intermediate 137-1

20 g of Bis(3-bromophenyl)diphenylsilane (CAS: 500886-98-6), 4.9 g of (Phenyl-d5)boronic acid (CAS: 215527-70-1), 30.35 mL of 2M K2CO3 aqueous solution, 2.34 g of Pd(PPh3)4 were dissolved in 200 mL of THF solvent, and stirred at 80° C. for 12 hours. After the reaction was completed, the reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography to obtain 14.5 g (yield 73%) of intermediate 137-1. Intermediate 137-1 was confirmed by LC-MS. (C30H18D5BrSi: M+1 496.53)


Synthesis of Intermediate 137-2

14.5 g of the Intermediate 137-1 were dissolved in 200 mL of THF solvent, and stabilized in −78° C. After 30 minutes, 14 mL of n-BuLi was slowly added dropwise thereto in −78° C. After 1 hour, 4.88 mL of trimethly borate was rapidly added thereto, the mixture was stirred at room temperature for 12 hours. 200 mL of 2M HCl was added thereto, and the mixture was stirred for 30 minutes to complete the reaction. The reaction solution was extracted, and the obtained organic layer was dried. The residue was separated and purified by column chromatography to obtain 9 g (yield: 80%) the Intermediate 137-2. Intermediate 137-2 was confirmed by LC-MS. (C30H20D5BO2Si M+1 462.40)


Synthesis of Intermediate 137-3

20 g of 9H-Carbazole-1,2,3,4,5,6,7,8-d8 (CAS: 38537-24-5) was dissolved in 150 mL of THF solvent, and stabilized at −0° C. 45.64 mL of n-BuLi was slowly added dropwise thereto in −78° C. After 30 minutes, 10.52 g of cyanuric chloride (CAS: 108-77-0) was dissolved in 50 mL of THF solvent, and rapidly added thereto at −0° C., when the precipitate was confirmed, and the mixture was stirred for 12 hours in 80° C. After the reaction was completed, the precipitate was purified through sublimation purification to obtain 19 g (yield 72%) Intermediate 137-3. Intermediate 137-3 was confirmed by LC-MS (C27D16ClN5: M+1 463.01).


Synthesis of Compound 137

After dissolving 2 g of Intermediate 137-2, 2 g of Intermediate 137-3, 4.33 mL of 2M K2CO3 aqueous solution, and 0.25 g of Pd(PPh3)4 in 20 mL of Toluene/Ethanol (v:v=4:1) solvent, the mixture was stirred for 12 hours at 110° C. After the reaction was completed, the reaction solution was extracted, and the resulting organic layer was dried. The residue was separated and purified by column chromatography, followed by recrystallization and sublimation purification to obtain 3.2 g (yield: 88%) of high-purity compound 137. Compound 137 was confirmed by LC-MS and 1H-NMR.


Synthesis Example 9: Synthesis of Compound 153



embedded image


Synthesis of Compound 153

2 g of 9,9′-(6-Chloro-1,3,5-triazine-2,4-diyl)bis(9H-carbazole) (CAS: 877615-05-9), 2.07 g of Intermediate 137-2, 4.49 mL of 2M K2CO3 aqueous solution and 0.26 g of Pd(PPh3)4 were dissolved in 20 mL of Toluene/Ethanol (v:v=4:1) solvent, followed by stirring for 12 hours at 110° C. After the reaction was completed, the reaction solution was extracted, and the resulting organic layer was dried. The residue was separated and purified by column chromatography, followed by recrystallization and sublimation purification to obtain 3.5 g (yield: 95%) of high-purity compound 153. Compound 153 was confirmed by LC-MS and 1H-NMR.


Synthesis Example 10: Synthesis of Compound 168



embedded image


embedded image


Synthesis of Intermediate 168-1

20 g of 1-Bromo-3-iodobenzene-2,4,5,6-d4 (GAS: 2363787-31-7), 8.85 g of (Phenyl-d5)boronic acid (GAS: 215527-70-1) 69.7 mL of 2M K2CO3 aqueous solution, and 0.25 g of Pd(PPh3)4 in 300 mL of THF solvent, stirred followed by stirring for 12 hours at 80° C. After the reaction was completed, the reaction solution was extracted, and the resulting organic layer was dried. After separation and purification of the residue by column chromatography, 12 g (yield 71%) of intermediate 168-1 was obtained. Compound 168-1 was confirmed by LC-MS. (C12D9Br: M+1 243.16)


Synthesis of Intermediate 168-2

A total of three reactions are prepared:


[Reaction 168A]


20 g of 1,3-Dibromobenzene-2,4,5,6-d4 (CAS: 1616983-07-3) was dissolved in 100 mL of diethyl ether and stabilized at −78° C. 33.34 mL of n-BuLi is slowly added dropwise at −78° C., followed by a low temperature reaction for 2 hours.


[Reaction 168B]


21.10 g of the dichlorodiphenylsilane (CAS: 80-10-4) was dissolved in 50 mL of diethyl ether and stabilized at −78° C. At −78° C., the reaction 168 Å solution is added in full to reaction 168B using a cannula.


[Reaction 168C]


20.19 g of the intermediate 168-1 was dissolved in 160 mL of THF and stabilized at −78° C. 33.34 mL of n-BuLi was slowly added dropwise at −78° C., after 1 hour, the entire amount of the reaction 168C solution is added to the reaction 168B using a cannula at −78° C. After 10 minutes, the mixture was stirred at room temperature for 12 hours. After the reaction was completed, the reaction solution was extracted, and the resulting organic layer was dried. After separation and purification of the residue by column chromatography, 24 g (yield 57%) of intermediate 168-2 was obtained. Compound 168-2 was confirmed by LC-MS. (C30H10D13BrSi: M+1 505.58)


Synthesis of Intermediate 168-3

After dissolving 24 g of the intermediate 137-3 in 230 mL of THF, it is stabilized at −78° C. After 30 minutes, 22.8 mL of n-BuLi was slowly added dropwise at −78° C. After 1 hour, 7.95 mL of trimethyl borate was quickly added and stirred at room temperature for 12 hours. Add 200 mL of 2M HCl aqueous solution and react for 30 minutes. The reaction solution was extracted, and the resulting organic layer was dried. After separation and purification of the residue by column chromatography, 21 g (yield 88%) of intermediate 168-3 was obtained. Compound 168-3 was confirmed by LC-MS.


Synthesis of Intermediate 168

2 g of Intermediate 137-3, 2.03 got Intermediate 168-3, 4.32 mL of 2M K2CO3 aqueous solution, and 0.25 g of Pd(PPh3)4 were dissolved in Toluene/Ethanol (v:v=4:1) solvent 20 mL, and the mixture was stirred for 12 hours at 110° C. After the reaction was completed, the reaction solution was extracted, and the resulting organic layer was dried. The residue was separated and purified by column chromatography, followed by recrystallization and sublimation purification to obtain 3.3 g of high-purity compound 168 (yield: 90%). Compound 168 was confirmed by LC-MS and 1H-NMR.



1H NMR and LC-MS of the compounds synthesized according to Synthesis Examples 1 to 10 are shown in Table 1. Synthesis methods for other compounds than the compounds shown in Table 1 may be readily recognized by those skilled in the technical field by referring to the synthesis paths and source material materials described above.











TABLE 1









LC-MS










Compound
H NMR (δ)
Calc.
Found













4
8.55 (d, 2H), 8.38 (d, 1H), 8.19 (d, 2H), 7.94 (d, 2H),
821.30
822.06



7.88 (s, 2H), 7.75 (d, 2H), 7.58-7.64 (m, 8H), 7.46-7.49 (m,





6H), 7.35-7.41 (m, 10H), 7.16-7.20 (m, 4H)




5
8.55 (d, 2H), 8.38 (d, 1H), 8.19 (d, 2H), 7.94 (d, 2H),
897.33
898.16



7.88 (s, 3H), 7.75 (d, 3H), 7.64 (m, 3H), 7.41-7.61 (m,





22H), 7.16-7.20 (m, 6H)




6
8.55 (d, 2H), 8.38 (d, 1H), 8.19 (d, 2H), 7.94 (d, 2H),
973.36
974.26



7.88 (s, 4H), 7.75 (d, 6H), 7.64 (m, 4H), 7.35-7.61 (m,





22H), 7.16-7.20 (m, 4H)




25
8.55 (d, 2H), 8.38 (d, 1H), 8.19 (d, 1H), 7.99 (d, 1H),
897.33
898.16



7.94 (d, 2H), 7.88 (s, 3H), 7.75-7.77 (m, 5H), 7.61-7.64 (m,





3H), 7.35-7.58 (m, 22H), 7.16-7.20 (m, 3H)




26
8.55 (d, 2H), 8.38 (d, 1H), 8.19 (d, 1H), 7.99 (m, 1H),
973.36
974.26



7.94 (d, 2H), 7.89 (s, 1H), 7.88 (s, 4H), 7.75-7.77 (m, 7H),





7.35-7.64 (m, 25H), 7.16-7.20 (m, 3H)




27
8.55 (d, 2H), 8.38 (d, 1H), 8.19 (d, 1H), 7.99 (m, 1H),
1049.39
1050.35



7.94 (m, 2H), 7.89 (s, 1H), 7.88 (s, 4H), 7.75-7.77 (m, 9H),





7.35-7.64 (m, 27H), 7.16-7.20 (m, 3H)




55
8.55 (d, 2H), 8.19 (d, 2H), 7.94 (m, 3H), 7.88 (s, 2H),
820.30
821.07



7.75 (d, 2H) 7.64 (m, 25H), 7.16-7.20 (m, 4H)




137
8.38 (d, 1H), 7.88 (s, 2H), 7.64 (m, 2H), 7.61 (d, 1H),
843.19
844.26



7.38 (m, 6H), 7.46-7.56 (m, 6H)




153
8.55 (d, 2H), 8.38 (d, 1H), 8.19 (d, 2H), 7.94 (d, 2H),
827.09
828.12



7.88 (s, 2H), 7.35-7.64 (m, 22H), 7.16-7.20 (m, 4H)




168
7.38-7.46 (m, 10H)
851.24
852.20









Example 1

As an anode, a Corning 15 Ω/cm2 (1,200 Å) ITO glass substrate was cut to a size of 50 mm×50 mm×0.5 mm, sonicated with isopropyl alcohol and pure water each for 10 minutes, and cleaned by exposure to ultraviolet rays and ozone for 10 minutes. The glass substrate was loaded onto a vacuum deposition apparatus.


NPD was vacuum-deposited on the ITO anode formed on the glass substrate to form a hole injection layer having a thickness of 300 Å, and TCTA was vacuum-deposited on the hole injection layer to form a hole transport layer having a thickness of 200 Å. CzSi was vacuum-deposited on the hole transport layer to form an emission auxiliary layer having a thickness of 100 Å.


Compound 4 and Ir(pmp)3 were co-deposited at a weight ratio of 92:8 on the emission auxiliary layer to form an emission layer having a thickness of 250 Å.


TSPO1 was deposited on the emission layer to form an electron transport layer having a thickness of 200 Å, TPBI was deposited on the electron transport layer to form a buffer layer having a thickness of 300 Å, LiF was deposited on the buffer layer to form an electron injection layer having a thickness of 10 Å, and Al was vacuum-deposited on the electron injection layer to form an electrode having a thickness of 3,000 Å, thereby completing the manufacture of a light-emitting device.




embedded image


embedded image


Examples 2 to 7 and Comparative Examples 1 to 4

Light-emitting devices were manufactured in the same manner as in Example 1, except that, in forming an emission layer, corresponding host compounds shown in Table 2 were used instead of Compound 4.


Evaluation Example 1

To evaluate characteristics of the light-emitting devices manufactured according to Examples 1 to 7 and Comparative Examples 1 to 4, the driving voltage at the current density of 50 mA/cm2 and luminescence efficiency thereof were measured. The driving voltage of each of the light-emitting devices was measured using a source meter (Keithley Instrument Inc., 2400 series), and the luminescence efficiency thereof was measured using a luminescence efficiency measurement apparatus C9920-2-12 of Hamamatsu Photonics Inc. In evaluating the luminescence efficiency, the luminance/current density was measured using a luminance meter that was calibrated for wavelength sensitivity, and the measured luminance/current density was converted into the maximum external quantum efficiency by assuming an angular luminance distribution (Lambertian) which introduced a perfect reflecting diffuser. The time taken to reach 95% of the initial luminance of Example 1 was regarded as 100%, and the relative lifetimes of Examples 2 to 7 and Comparative Examples 1 to 4 were measured. The evaluation results of the characteristics of the light-emitting devices are shown in Table 2.














TABLE 2









Maximum





Driving
Luminescence
external




Host in
voltage
efficiency
quantum
Relative



emission layer
(V)
(cd/A)
efficiency (%)
Lifetimes (%)







Example 1
Compound 4
4.2
27.4
26.3
100


Example 2
Compound 5
4.1
28.1
27.9
 90


Example 3
Compound 6
4.0
27.8
26.4
 86


Example 4
Compound 25
4.2
26.4
25.9
 88


Example 5
Compound 26
4.1
27.1
26.6
 76


Example 6
Compound 27
4.0
26.3
26.0
 70


Example 7
Compound 55
4.3
21.2
20.7
 70


Comparative
Compound R1
4.5
16.3
15.7
 25


Example 1







Comparative
Compound R2
5.2
15.0
15.9
 15


Example 2







Comparative
Compound R3
4.1
15.5
15.1
 13


Example 3







Comparative
Compound R4
4.6
14.7
14.9
 20


Example 4







embedded image


embedded image


embedded image


embedded image








Referring to Table 2, it was confirmed that the light-emitting devices of Examples 1 to 7 had low driving voltage, excellent luminescence efficiency, and excellent maximum external quantum efficiency and lifespan, as compared with the light-emitting devices of Comparative Examples 1 to 4.


Example 8

As an anode, a Corning 15 Ω/cm2 (1,200 Å) ITO glass substrate was cut to a size of 50 mm×50 mm×0.5 mm, sonicated with isopropyl alcohol and pure water each for 5 minutes, and cleaned by exposure to ultraviolet rays and ozone for 30 minutes. The glass substrate was loaded onto a vacuum deposition apparatus.


HATCN was vacuum-deposited on the ITO anode formed on the glass substrate to form a hole injection layer having a thickness of 100 Å, and BCFN was vacuum-deposited on the hole injection layer to form a hole transport layer having a thickness of 600 Å. SiCzCz was vacuum-deposited on the hole transport layer to form an emission auxiliary layer having a thickness of 50 Å.


SiCzCz, Compound 4 and PtON-TBBI were co-deposited at a weight ratio of 60:27:13 on the emission auxiliary layer to form an emission layer having a thickness of 350 Å.


mSiTrz was deposited on the emission layer to form an electron transport layer having a thickness of 50 Å, mSiTrz and LiQ were co-deposited at a weight ratio of 1:1 on the electron transport layer to form a buffer layer having a thickness of 350 Å, LiF was deposited on the buffer layer to form an electron injection layer having a thickness of 15 Å, and Al was vacuum-deposited on the electron injection layer to form an electrode having a thickness of 80 Å, thereby completing the manufacture of a light-emitting device.




embedded image


embedded image


Examples 9 to 11 and Comparative Examples 5 to 8

Light-emitting devices were manufactured in the same manner as in Example 8, except that, in forming an emission layer, corresponding compounds shown in Table 3 were used instead of Compound 4.


Evaluation Example 2

To evaluate characteristics of the light-emitting devices manufactured according to Examples 8 to 11 and Comparative Examples 5 to 8, the driving voltage at the current density of 50 mA/cm2 and luminescence efficiency thereof were measured. The driving voltage of each of the light-emitting devices was measured using a source meter (Keithley Instrument Inc., 2400 series), and the luminescence efficiency thereof was measured using a luminescence efficiency measurement apparatus 09920-2-12 of Hamamatsu Photonics Inc. In evaluating the luminescence efficiency, the luminance/current density was measured using a luminance meter that was calibrated for wavelength sensitivity, and the measured luminance/current density was converted into the maximum external quantum efficiency by assuming an angular luminance distribution (Lambertian) which introduced a perfect reflecting diffuser. In addition, the time taken to reach 95% of the initial luminance of Example 1 was regarded as 100%, and the relative lifetimes of Examples 8 to 11 and Comparative Examples 5 to 8 were measured. The evaluation results of the characteristics of the light-emitting devices are shown in Table 3.














TABLE 3









Maximum





Driving
Luminescence
external




Host in
voltage
efficiency
quantum
Relative



emission layer
(V)
(cd/A)
efficiency (%)
Lifetimes (%)







Example 8
Compound 4
4.0
27.3
26.8
130


Example 9
Compound 137
4.1
27.8
27.2
160


Example 10
Compound 153
4.1
26.5
25.8
145


Example 11
Compound 168
4.2
27.4
26.3
170


Comparative
Compound R1
4.5
16.4
15.7
 35


Example 5







Comparative
Compound R2
4.6
15.5
15.1
 30


Example 6







Comparative
Compound R3
4.0
15.5
14.0
 24


Example 7







Comparative
Compound R4
4.6
15.0
14.9
 22


Example 8







embedded image


embedded image


embedded image


embedded image








Referring to Table 3, it was confirmed that the light-emitting devices of Examples 8 to 11 had low driving voltage, excellent luminescence efficiency, excellent maximum external quantum efficiency and lifespan, as compared with the light-emitting devices of Comparative Examples 5 to 8.


Embodiments have been disclosed herein, and although terms are employed, they are used and are to be interpreted in a generic and descriptive sense only and not for purpose of limitation. In some instances, as would be apparent by one of ordinary skill in the art, features, characteristics, and/or elements described in connection with an embodiment may be used singly or in combination with features, characteristics, and/or elements described in connection with other embodiments unless otherwise specifically indicated. Accordingly, it will be understood by those of ordinary skill in the art that various changes in form and details may be made without departing from the spirit and scope of the disclosure as set forth in the claims.

Claims
  • 1. A light-emitting device comprising: a first electrode;a second electrode facing the first electrode; andan interlayer between the first electrode and the second electrode, whereinthe interlayer comprises: an emission layer; andat least one heterocyclic compound represented by Formula 1:
  • 2. The light-emitting device of claim 1, wherein the first electrode is an anode,the second electrode is a cathode,the interlayer further comprises: a hole transport region between the emission layer and the first electrode; andan electron transport region between the emission layer and the second electrode,the hole transport region comprises a hole injection layer, a hole transport layer, an emission auxiliary layer, an electron blocking layer, or a combination thereof, andthe electron transport region comprises a buffer layer, a hole blocking layer, an electron control layer, an electron transport layer, an electron injection layer, or a combination thereof.
  • 3. The light-emitting device of claim 1, wherein the emission layer comprises the at least one heterocyclic compound.
  • 4. The light-emitting device of claim 3, wherein the emission layer further comprises an organometallic compound represented by Formula 401:
  • 5. The light-emitting device of claim 4, wherein the light-emitting device has a maximum external quantum efficiency equal to or greater than about 20%.
  • 6. An electronic apparatus comprising: the light-emitting device of claim 1; anda thin-film transistor, whereinthe thin-film transistor comprises a source electrode and a drain electrode, andthe first electrode of the light-emitting device is electrically connected to the source electrode or the drain electrode.
  • 7. The electronic apparatus of claim 6, further comprising a color filter, a color conversion layer, a touch screen layer, a polarizing layer, or a combination thereof.
  • 8. A heterocyclic compound represented by Formula 1:
  • 9. The heterocyclic compound of claim 8, wherein X4 is C(R4),R4 is a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, andR10a is the same as described in Formula 1.
  • 10. The heterocyclic compound of claim 8, wherein E11, E12, and E21 to E23 are each independently: a C1-C20 alkyl group;a C1-C20 alkyl group substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C10 alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, or a combination thereof; ora cyclopentenyl group, an adamantanyl group, a norbornanyl group, a phenyl group, a pentalenyl group, a naphthyl group, an azulene group, an indacenyl group, an acenaphthyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a heptalenyl group, a naphthacenyl group, a picenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, an ovalenyl group, an indenyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, an indenophenanthrenyl group, or an indenoanthracenyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a tetrahydronaphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, an azadibenzosilolyl group, —Si(Q31)(Q32)(Q33), —B(Q31)(Q32), —P(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or a combination thereof, andQ31 to Q33 are each the same as described in Formula 1.
  • 11. The heterocyclic compound of claim 8, wherein L11 is a single bond, andb11 is 1.
  • 12. The heterocyclic compound of claim 8, wherein L24 is a single bond, andb24 is 1.
  • 13. The heterocyclic compound of claim 8, wherein R1 to R4, R11 to R13, and R21 to R23 are each independently: hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, or a C1-C20 alkoxy group;a C1-C20 alkyl group or a C1-C20 alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C10 alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, or a combination thereof,a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a tetrahydronaphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, or an azadibenzosilolyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a tetrahydronaphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, an azadibenzosilolyl group, —Si(Q31)(Q32)(Q33), —B(Q31)(Q32), —P(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or a combination thereof; or—Si(Q1)(Q2)(Q3), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2), andQ1 to Q3 and Q31 to Q33 are each independently:—CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H, or —CD2CDH2; oran n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a triazinyl group, a carbazolyl group, a dibenzofuranyl group, or a dibenzothiophenyl group, each unsubstituted or substituted with deuterium, a C1-C10 alkyl group, a phenyl group, a biphenyl group, a pyridinyl group, a pyrimidinyl group, pyridazinyl group, a pyrazinyl group, a triazinyl group, a carbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, or a combination thereof.
  • 14. The heterocyclic compound of claim 8, wherein the sum of a21 to a23 is 1 or more.
  • 15. The heterocyclic compound of claim 8, wherein the sum of a11 and a12 is an integer from 0 to 2.
  • 16. The heterocyclic compound of claim 8, wherein in Formula 1, a moiety represented by
  • 17. The heterocyclic compound of claim 8, wherein in Formula 1, a moiety represented by
  • 18. The heterocyclic compound of claim 8, wherein in Formula 2, a moiety represented by
  • 19. The heterocyclic compound of claim 8, wherein a group represented by Formula 2 is a group represented by one of Formulae 2-1 to 2-3:
  • 20. The heterocyclic compound of claim 8, wherein the heterocyclic compound represented by Formula 1 is one of Compounds 1 to 168:
Priority Claims (2)
Number Date Country Kind
10-2022-0001449 Jan 2022 KR national
10-2022-0078481 Jun 2022 KR national